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AutophagyCalmodulin (CaM) is a ubiquitous Ca2+ receptor protein mediating a large number of signaling processes in all
eukaryotic cells. CaMplays a central role in regulating amyriad of cellular functions via interaction withmultiple
target proteins. This review focuses on the action of CaM and CaM-dependent signaling systems in the control of
vertebrate cell proliferation, programmed cell death and autophagy. The signiﬁcance of CaM and interconnected
CaM-regulated systems for the physiology of cancer cells including tumor stem cells, and processes required for
tumor progression such as growth, tumor-associated angiogenesis and metastasis are highlighted. Furthermore,
the potential targeting of CaM-dependent signaling processes for therapeutic use is discussed.
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Calmodulin (CaM) is considered the major regulator of Ca2+-
dependent signaling in all eukaryotic cells. Its ubiquitous distribution,
its high conservation during evolution, its broad spectrum of functions
and the fact that it is essential in all so far tested organisms underlaye 3-methyl-5-3-(4,4-diphenyl-1-
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ights reserved.the importance of this EF-hand type Ca2+-binding protein in cell phys-
iology. Since its discovery as a cyclic nucleotide phosphodiesterase
(PDE) activator in the early '70 of the past century [1,2], a vast amount
of data has been accumulated on its important function in the control
of numerous physiological processes such as e.g. cell motility, cytoskel-
eton architecture and function, cell proliferation, apoptosis, autophagy,
metabolic homeostasis, phospholipid turnover, protein folding, phos-
phorylation/dephosphorylation of proteins, ions transport, osmotic
control, reproductive processes, muscle contraction and gene expres-
sion among others. Much has been learned during the recent years on
the structure and functionality of CaM and its target proteins, the dy-
namics of Ca2+ binding and the different Ca2+-dependent as well as
Ca2+-independent mechanisms of interaction with its multiple targets
(reviewed in Refs. [3–8]). One reason for the unprecedented diversity
of CaM functions is connected with its ability to interact with several
hundred different target proteins and to modulate their activity in
many differentways. In this reviewwewill describe accumulated infor-
mation and recent advances on the action of CaM and different CaM-
dependent systems in the control of cell proliferation, programmed
cell death and autophagy, with a particular focus on the implication of
these mechanisms for the physiology of tumor cells.
The transient increase in the concentration of free Ca2+ in the cyto-
sol and its spread to the nucleus upon cell activation by a broad range of
stimuli including mitogenic factors and other agonists has been recog-
nized as the principal event responsible for the initiation of many signal
transduction processes. The transport systems that control the concen-
tration of Ca2+ in the nucleus are of upmost importance for cell
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also controls the activity ofmany transcription factors (reviewed in Refs.
[9,10]). The study of the complex network of Ca2+-binding proteins and
their interactions, denoted as 'calciomics, try to understand themultiple
effects of Ca2+ leading to changes in cell physiology (reviewed in Ref.
[11]). Besides CaM other Ca2+-binding proteins including e.g. calpains
(reviewed in Ref. [12]), ALG-2 (apoptosis-linked gene 2 product)
(reviewed in Ref. [13]), sorcin (reviewed in Ref. [14]), S-100 proteins
(reviewed in Ref. [15]), oncomodulin [16,17] and annexins (reviewed
in Ref. [18]) also play important roles in signal transduction leading to
the control of cell proliferation as well as cell death. However, this
topic lies outside the scope of this review. The activation of Ca2+-
binding proteins occurs by Ca2+ entry into the cytosol through the
temporospatial opening of Ca2+ channels initiated by a variety of signal-
ing molecules. They may be derived from the metabolism of phospho-
lipids, such as inositol-1,4,5-trisphosphate (IP3) resulting from the
hydrolysis of phosphatidylinositol 4,5-bisphosphate by phospholipase
Cγ (PLCγ) (reviewed in Refs. [19–24]), and leukotriene C4 formed
from arachidonic acid released by the action of phospholipase A2
(PLA2) on phospholipids (reviewed in Refs. [25–27]). Additional mes-
sengers implicated in Ca2+ mobilization are the nucleotides cyclic
ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate
(NAADP) derived from NAD+ and NADP+, respectively. They activate
ryanodine receptors located at the endo(sarco)plasmic reticulum and
two-pore channels located at endo-lysosomes, respectively (reviewed
in Refs. [28–31]). Another important Ca2+ mobilizing agent is ADP-
ribose (ADPR), synthesized by the poly(ADP-ribose) polymerase 1/2-
poly(ADP-ribose) glycohydrolase (PARP1/2-PARG) pathway. ADPR acts
on transient receptor potential melastatin 2 (TRPM2) Ca2+ channels lo-
cated at the plasmamembrane and lysosomes regulating autophagy and
apoptosis induced by oxidative stress [32] (reviewed in Ref. [33]).
The feedback control of the opening/closing states of the abovemen-
tioned channels by differentmechanisms results in Ca2+ inﬂuxes of dis-
tinct intensity, spatial distribution and duration, either as single
transients or as oscillatory phenomena. These events are orchestrated
among other factors by the assembly of clustered channels in units of
different sizes and by the counter activity of Ca2+ transport systems in-
volved in the sequestration of Ca2+ into intracellular stores and efﬂux to
the extracellularmedium. Distinct pumps, denoted sarco(endo)plasmic
reticulum Ca2+-ATPase (SERCA) and secretory pathway Ca2+-ATPase
(SPCA) (reviewed in Refs. [34,35]) mediate Ca2+ uptake into the endo-
plasmic reticulum (ER) and the Golgi secretory pathway, respectively.
Ca2+ sequestration into themitochondria ismediated by an electropho-
retic Ca2+ uniporter (mCU) and its release by Na+(H+)/Ca2+ ex-
changers (reviewed in Refs. [36–40]). Removal of Ca2+ from the cell is
under the control of a Na+/Ca2+ exchanger (reviewed in Ref. [41])
and the CaM-dependent Ca2+-ATPase located at the plasmamembrane
(reviewed in Refs. [35,42,43]). The entry of Ca2+ into the nucleoplasm,
in addition to the nuclear pore pathway, is mostly mediated by IP3 and
ryanodine receptors located at the nuclear envelope-ER network
[10,38,44–46]. Ca2+ re-uptake into this compartment is mediated by a
SERCA [10,44,45] and a nuclear Na+/Ca2+ exchanger regulated by
ganglioside M1 (monosialotetrahexosylganglioside) (GM1) [47].
Many Ca2+ transport systems in the cell are directly regulated by CaM
(Fig. 1), counting for example the plasma membrane Ca2+-ATPase
(reviewed inRefs. [35,42,43]), diverse Ca2+ channels such as IP3 receptors
[48], ryanodine receptors [49], Orai/CRAC (calcium release-activated
calcium) channels [50,51] and its regulator stromal-interacting molecule
1 (STIM1) [52], voltage-gated Ca2+ channels (reviewed in Ref. [53]),
TRPM2 [54] and other transient receptor potential (TRP) channels
(reviewed in Ref. [55]), as well as gap junction channels and hemichan-
nels (reviewed in Ref. [56]). Furthermore, the hyperpolarizing Ca2+-
dependent K+ channels, that favor Ca2+ entry via hyperpolarization-
sensitive channels, are also CaM-dependent (reviewed in Ref. [57]).
Intracellular Ca2+ signals can be propagated in tissues as intercellu-
lar Ca2+ waves by mechanisms involving the intercellular transport ofcalcium-mobilizing messengers, e.g. IP3, across gap-junction channels,
each formed by six connexin molecules. Some connexins are CaM-
binding proteins, e.g. connexin-32 and connexin-43 [58,59]. Alterna-
tively, the release of ATP to the extracellular ﬂuid across connexin hemi-
channels and maxi-anion channels or by vesicular release may
stimulate P2 receptors in neighboring cells where additional Ca2+ sig-
nals are elicited (reviewed in Ref. [60]). Moreover, the open/closed
states of connexin hemichannels appear to be controlled by both the ex-
tracellular and intracellular concentrations of Ca2+ [61], and Ca2+ can
itself permeate the hemichannels as demonstrated for example with
reconstituted connexin 26 in liposomes [62].
The increase in intracellular Ca2+ triggers the formation of the Ca2+/
CaM complex, as monitored in intact cells [63,64], followed by modula-
tion of the functionality of the target proteins (Fig. 2). Saucermann and
Bers [65] have proposed that there are two distinct pools of CaM in the
cell: one, named ‘dedicated’, formed by CaMmolecules already tethered
to their targets (e.g. Ca2+ channels) ready to activate them upon Ca2+
availability; and the other minor pool, ‘named promiscuous’ formed
by free CaM molecules in the cytosol, which may interact and regulate
CaM-binding protein upon Ca2+ binding (Fig. 2). Frequently, the inter-
action of Ca2+/CaM with their targets implicate wrapping the CaM-
binding region of the target by the CaM molecule collapsed by bending
around its central linker α-helix and bringing the N- and C-globular re-
gions closer to each other, as for example with CaM-dependent kinase
(CaMK)-I [66] (Fig. 3), CaMK-II [67] or calcineurin (CaN) also denoted
protein phosphatase 2B (PP2B) [68]. CaMK-II, when activated by Ca2+
and CaMconverts itself into a Ca2+-independent enzyme,with function
inmany biological processes. Table 1 summarizes a selection of themost
relevant CaM-binding proteins controlling the processes to be discussed
in the different chapters of this review.
Of interest for the purpose of this review is the fact that in tumor and
transformed cells themobilization of Ca2+ is altered,whichhas important
implications for tumor development and progression (reviewed in Refs.
[69,70]). Also important in this context is the anomalous intracellular con-
centration of CaM and other Ca2+-binding proteins in tumor cells [71,72].
As described in earlier reviews [73–79], an inﬂux of extracellular Ca2+
into the cell upon growth factors stimulation is essential for initiating cell
proliferation. The Ca2+/CaMcomplex plays a transducing role in signaling
events by directly or indirectly controlling mitogenic pathways and the
cell cycle machinery, most signiﬁcantly acting at the G1/S transition and
at the G2 andMphases (discussed in detail in Section 3.6). This implicates
multiple molecular mechanisms responsible for the progression of the
cell cycle andother relevant processes required formitogenesis. Processes
such as the activation of cyclin-dependent kinase (Cdk)/cyclin complexes,
nucleotide metabolism, DNA synthesis, chromosomal reorganization and
cytokinesis are dependent on the presence of CaM, which acts to a major
degree through distinct CaM-dependent protein kinases and CaM-
dependent protein phosphatases, most prominently CaN.
Early observations identiﬁed Ca2+ overload as a noxious signal that
can induce cell death. Thismay occur by variousways including necrosis
and apoptosis (discussed in detail in Section 4). More recently a prom-
inent functional role played by Ca2+ and Ca2+-sensor proteins in au-
tophagy has been identiﬁed, as for example [80] (reviewed in Ref. [81]
and discussed in detail in Section 5). Ca2+-dependent signal transduc-
ing mechanisms during apoptosis and autophagy involve different
CaM-regulated systems with important contributions by mitochondria,
the endoplasmic reticulum and lysosomes, all able to mobilize Ca2+
(reviewed in Refs. [82–85]).
Altered CaM-dependent cell cycle regulation and proliferation has
been observed in many tumor cells, and targeting CaM and/or the
CaM-dependent systems has been considered useful strategies for
potential therapeutic intervention in cancer (discussed in detail in
Section 6.5). Inhibition of CaM function or its targets with chemical
antagonists or downregulating its expression using interfering RNA
technology, alone or in combination with different chemotherapeutic
agents, have recently been attempted, albeit with modest success; for
nNCX
Fig. 1. The Ca2+ transport systems. The scheme depicts themajor transport systemsmobilizing Ca2+ at the plasmamembrane, the endoplasmic reticulum (ER), mitochondria (Mito), the
nucleus (Ncl), theGolgi, endolysosomes (ELS), and lysosomes (Lyso), highlighting the ones regulated by calmodulin (CaM). The effectors activating the different transport systems are also
indicated. cADPR, cyclic ADP-ribose; CAKC, Ca2+-activated K+ channel; CaM, calmodulin; CRACM, calcium release-activated calcium channel molecule (Orai); GJ, gap junction; GJH, gap
junction hemichannel; GM1, ganglioside M1 (monosialotetrahexosylganglioside); IP3, inositol-1,4,5-trisphosphate; IP3R, IP3 receptor; LC4, leukotriene C4; mCU, mitochondrial Ca2+
uniport; mN(H)CX, mitochondrial Na+/Ca2+ or H+/Ca2+ exchangers; NAADP, nicotinic acid adenine dinucleotide phosphate; nNCX, nuclear Na+/Ca2+ exchanger; NCX, Na+/Ca2+ ex-
changer; PMCA, plasma membrane Ca2+-ATPase; RyR, ryanodine receptor; SERCA, sarco(endo)plasmic reticulum Ca2+-ATPase; SPCA, secretory pathway Ca2+-ATPase; STIM, stromal-
interactingmolecule; TPC, two-pore channel; TRP, transient receptor potential; TRPM2, TRPmelastatin 2; VICC, voltage-independent Ca2+ channel; VSCC, voltage-sensitive Ca2+ channel.
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break inducer bleomycin [86] (reviewed in Ref. [87]).
Thedetailed elucidationof theCaM-dependent control of both cell pro-
liferation and cell death during cancer development and progression is a
major research goal. The complexity of CaM actions complicates the iden-
tiﬁcation of particular CaM-dependent routes that could be both speciﬁc
and effective targets in tumor cells for therapeutic purposewithout greatly
disturbing the physiology of normal cells. Understanding the molecular
mechanisms underlying the CaM-dependent systems potentially involved
in the enhancedproliferative capacity of tumor cells, the deﬁciencies in the
onset of apoptosis upon DNA damage, the enhanced migration and
invasiveness, and/or the angiogenesis associated with tumor growth,
may lead to identifying new strategies for therapeutic intervention. In
this review we will describe what it is known so far about the action of
CaM and CaM-dependent systems in the control of cell proliferation, pro-
grammed cell death and autophagy of tumor and non-tumor cells.
2. Calmodulin and the proliferation of lower eukaryotic cells
Our understanding of the role of CaM in cell proliferation has been
greatly aided by the important pioneer studies done in phylogeneticallylower eukaryotic organisms, such as the baker's yeast Saccharomyces
cerevisiae, the ﬁssion yeast Schizosaccharomyces pombe and theﬁlamen-
tous fungi Aspergillus nidulans among others (reviewed in Refs.
[88–91]). Therefore, although this reviewwill be concernedwith the ac-
tions of CaM on the proliferation of vertebrate cells and their dismissal
by programmed cell death and other mechanisms, it is pertinent to
make some brief remarks highlighting the action of CaMon the prolifer-
ation of these microorganisms to emphasize evolutionary connections
and similarities as well as differences of the implicated mechanisms.
The need for CaM during cell division was ﬁrst demonstrated in a
lethal mutant of S. cerevisiae where CaM expression was disrupted by
knocking out its single gene or conditionally-repressing its expression
upon galactose withdrawal [92,93]. Interestingly, expression of the N-
terminal or the C-terminal halves of CaM in the CaM-nullmutantwas suf-
ﬁcient for rescuing cell viability, although in a temperature-dependent
manner [94]. In addition, a temperature-sensitive S. cerevisiae mutant,
with two point mutations in the CaM gene (I100D and E104V), when
synchronized at the G1 phase progressed through the cell cycle but
retained very poor viability after the ﬁrst mitosis. However, this mutant
could form colonies when cultured at the permissive temperature,
but lost viability when synchronized in G2/M and shifted to the non-
Fig. 2. Activation of calmodulin and target systems. The scheme depicts the sequential saturation of calmodulin (CaM) by increasing concentrations of cytosolic free Ca2+ (blue triangles)
upon activation of a cell surface receptor (R) by an agonist; and the sequential activation of high and lowafﬁnity protein targets by the Ca2+/CaMcomplex or the activation of tethered CaM
and its target protein upon binding of Ca2+. Activation of some target proteins by Ca2+-free CaM (apo-CaM) is also shown.
Fig. 3. Interaction of calmodulin with a CaMK-I peptide. Model of Ca2+/CaM (pink) collapsed around a peptide (blue/yellow barrel labeled P) corresponding to the CaM-binding site of
CaMK-I (MMDB ID: 21255 PDB ID: 1MXE). CaM methionine residues are labeled in yellow. The N- and C- termini of CaM and Ca2+ ions are indicated.
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Table 1
Calmodulin-binding proteins involved in functions relevant in cell proliferation, apoptosis,
autophagy and tumor progression.
CaM-binding protein Major functions References
(on CaM binding)
14-3-3ε Proliferation [269]
Aurora A/B Proliferation [345,346]
AKAP12 Proliferation
Cell migration
(metastasis)
[285]a
Akt Cell survival
Autophagy
[499]
ASPM Proliferation [364]
CaN Proliferation
Apoptosis
Autophagy
[243]a
CaMK-I Proliferation
Autophagy
[227]a
CaMK-II Proliferation
Apoptosis
[227]a
CaMK-III (eEF2K) Proliferation
Autophagy
[227]a
CaMK-IV Proliferation
Apoptosis
Autophagy
[227]a
CaMKK Proliferation
Apoptosis
Autophagy
[220]a
CaMKLK Apoptosis [391]
CAMTA1/2 Proliferation [289]a
C/EBP-β Proliferation
Autophagy
[291]
Cdk5 Proliferation [310]
c-FLIP Apoptosis [450]
Connexins (32 and 43) Intercellular
communication
[58,59]
Cyclin E1 Proliferation [312]
DAPK1/2 Apoptosis
Autophagy
[373]a
DRP-1 Apoptosis
Autophagy
[373]a
EGFR (ErbB1) Proliferation
Differentiation
Cell migration
Cell survival
[174]
[175]a
ErbB2 Proliferation
Differentation
Cell migration
(metastasis)
Cell survival
Autophagy
[176]
FADD Proliferation
Apoptosis
Autophagy
[286]
Fas (CD95) Apoptosis [443]
FKBP38 Apoptosis
Autophagy (?)
[410]
gp160
(HIV envelope protein)
Apoptosis [436]
Grb7 Cell migration
(metastasis)
Cell adhesion
Proliferation
Angiogenesis
(tumor-associated)
[279]
HRPAP20 Proliferation
Apoptosis
Tumor cells invasion
[552]
Hsp70 Proliferation
Apoptosis
Autophagy
[325]
Hsp90 Proliferation [322]
InsR Metabolism
Proliferation
[179]
IQGAP1 Proliferation
Cell adhesion
(metastasis)
[282]
IRS1/2 Metabolism
Proliferation
[630]
Table 1 (continued)
CaM-binding protein Major functions References
(on CaM binding)
Kir/Gem Proliferation
Cytoskeletal
organization
(metastasis)
[199]
K-Ras B Proliferation [193]
p21Cip1/Waf1 Proliferation [315]
p35 (Cdk5 neural activator) Proliferation [311]
p68 RNA helicase EMT
Proliferation
Cell migration
(metastasis)
[555]
Cyclic nucleotides PDE Proliferation [1,2]
PI3K Cell survival [501]
PI3K-III (VPS34) Autophagy [631]
Plk1 Proliferation [338]
Src (v- and c-) Proliferation
Cell migration
[250,251]
TrkA Proliferation
Cell survival
Differentiation
[178]
AKAP12, A-kinase anchor protein 12; ASPM, abnormal spindle-like microcephaly-
associated protein; CaN, calcineurin; CaMK-I/II/III/IV, CaM-dependent kinases I/II/III/IV;
CaMKK, CaM-dependent kinase kinase; CaMKLK, CaM-dependent protein kinase-like ki-
nase; Cdk5, cyclin-dependent kinase 5; c-FLIP, cellular FLICE-like inhibitory protein;
DAPK1/2, death-associated protein kinases 1/2; DRP-1, DAPK-related protein kinase 1;
EGFR (ErbB1), epidermal growth factor receptor; EMT, epithelial/mesenchymal transition;
ErbB2, erythroblastic leukemia viral oncogene homologue 2; FADD, Fas-associated protein
with death domain; Fas, TNF receptor superfamilymember 6; FKBP38, FK506-binding pro-
tein 38; Grb7, growth factor receptor bound protein 7; HIV, human immunodeﬁciency
virus; HRPAP20, hormone-regulated proliferation-associated protein 20; Hsp70, heat
shock protein 70; Hsp90, heat shock protein 90; InsR, insulin receptor; IRS1/2, insulin
receptor substrates 1/2; IQGAP1, IQ-containing Ras GTPase-activating-like protein 1;
PDE, phosphodiesterase; PI3K, phosphatidylinositol 3-kinase; PI3K-III, phos-
phatidylinositol 3-kinase type III; TrkA, nerve growth factor receptor A.
a Review article.
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cycle progression [95].
The conditional repression of the single CaM gene in the yeast S.
pombe [96] and in a genetically manipulated strain of A. nidulans [97],
or the insertional disruption of the CaM gene in the human pathogenic
fungus Cryptococcus neoformans [98], blocked the proliferation of these
organisms, and arrested the cell cycle at the G2 phase in the case of A.
nidulans [97]. Moreover, even though Ca2+ binding to CaM is not neces-
sary for the growth of S. cerevisiae [99], mutations which block Ca2+
binding to CaM lead to the loss of viability when proliferation was
arrested by themating pheromoneα-factor [100]. The spindle pole pro-
tein Nuf1p/Spc110p of S. cervisiae was demonstrated to be an essential
target for CaM during mitosis, even when all the Ca2+-binding sites
were inactivated [101]. The CaMof S. cerevisiae has only three functional
Ca2+-binding motifs because site IV is unable to bind Ca2+ [102–105].
Its heterologous expression in S. pombe, endogenously expressing CaM
with four functional Ca2+-binding sites, did not support growth in con-
trast to the expression of vertebrate CaM in S. pombe [106]. This indi-
cates a major functional difference between S. cerevisiae and S. pombe
CaMs.
In S. cerevisiae, CaM concentrates at regions of cell growth, as for ex-
ample the tip developed upon treatment with the α-factor. It is associ-
ated to actin ﬁlaments during progression of the cell cycle in a Ca2+-
independent manner, as similar localization was attained expressing a
null Ca2+-binding CaM mutant [107]. Furthermore, Ca2+-independent
binding of CaM to the IQ motif of myosin Myo2p was also found at the
sites of polarized cell growth [108].
The implication of the CaM target calcineurin (CaN) in the growth of
S. cerevisiae is contentious. Disruption of the genes encoding the catalyt-
ic subunit of the two isoforms of this phosphatase does not affect cell vi-
ability under normal growth conditions [109,110]. On the other hand,
disrupting the regulatory subunit of CaN enhances the sensitivity
403M.W. Berchtold, A. Villalobo / Biochimica et Biophysica Acta 1843 (2014) 398–435towards the mating α-factor leading to a cell cycle arrest at the G2/M
boundary [100] (reviewed in Ref. [111]). CaN controls aswell the degra-
dation of the transcription factor Yap1p, a suppressor of Ca2+ sensitivity
in S. cervisiae, to ensure a delay of the cell cycle at G2when this organism
is exposed to high concentrations of Ca2+ [112].
CaM kinases (CaMKs) positively contribute to cell survival when
S. cerevisiae is in a non-proliferating state [100]. In A. nidulans CaMK is
required for cell proliferation, particularly for the G2/M transition
[113]. However, the expression of a constitutively active form of this
kinase induces the premature activation of the fungus-equivalent of
the vertebrate Cdk1(cdc2)/cyclin B complex when the cells are still in
G0/G1 and hence prevents entry into the S phase and further cell cycling
[114]. CaM may participate in other growth-related processes in lower
eukaryotes, as for example in the control of the number of nuclei in
the slime mold Dictyostelium upon binding to nucleomorphin during
mitosis [115,116] (reviewed in Ref. [117]).
The combined observations in yeast/fungi brieﬂy described above
underscore the fact that CaM plays a central role in growth regulation
of lower eukaryotic organisms and that Ca2+/CaM-dependent
protein phosphorylation/dephosphorylation mechanisms are central
for regulating cell proliferation.3. Calmodulin and the proliferation of vertebrate cells
3.1. Calcium is required for cell proliferation
A variety of mitogenic factors and other effectors, including some
hormones, stimulate vertebrate cell growth upon activation of their
respective receptors by inducing an early and transient increase of the
intracellular concentration of free Ca2+ [118,119]. The activation of dif-
ferent Ca2+ channels located at the plasma membrane is essential for
the correct regulation of cell proliferation. Alterations of external Ca2+
inﬂux has been observed in transformed and cancerous cells (reviewed
in Refs. [120,121]). Store-operated Ca2+ entry is of vital importance for
cell proliferation. Inhibition of cell cycle progression and cell growth has
been demonstrated by silencing the expression of players implicated in
the regulation of Ca2+ entry, such as the calcium sensor STIM1 and the
Ca2+ channels Orai1 or TRP canonical 6 (TRPC6) in a variety of tumor
cells including human hepatomas and cervical carcinomas [122–124].
In contrast, silencing STIM1 and Orai1 in human breast adenocarcinoma
MDA-MB-231 cells did not affect their proliferation rate [125], suggest-
ing that Ca2+ mobilization from other plasma membrane channels or
from intracellular storesmay compensate in these cells, although silenc-
ing these systems affected cellmigration and themetastasic potential of
a variety of tumor cells [123–125].
Ca2+ regulates important processes implicated in cell proliferation
by the formation of a complex with CaM and other Ca2+-binding pro-
teins, targeting proteins that control cell proliferation. Some high-
afﬁnity CaM targets are readily activated at low Ca2+ concentrations,
as they require low levels of Ca2+, while the low-afﬁnity ones are only
activated at higher Ca2+ levels, solely attained in speciﬁc subcellular
regions or during restricted time periods when global Ca2+ concentra-
tions reach higher levels [64] (Fig. 2). Many transport systems, respon-
sible for balancing the cytosolic free Ca2+ concentration, are under
feedback control by the Ca2+/CaM complex (Fig. 1). The most promi-
nent systems regulated in this manner are the plasma membrane
Ca2+-ATPase (PMCA) (reviewed in Refs. [42,43]), a large number of
plasma membrane Ca2+ channels (reviewed in Ref. [126]) and some
family members of the TRP channels located at the endo(sarco)plasmic
reticulum and other intracellular membranes as well as the plasma
membrane (reviewed in Refs. [33,55]). Of relevance for cell prolifera-
tion, a Ca2+/CaM-regulated feedback control of K+ exit has been
demonstrated, as blocking Ca2+/CaM-activated K+ channels inhibited
T cells proliferation. The resulting hyperpolarization facilitated further
Ca2+ entry through a membrane potential-driven mechanism [127].3.2. Calmodulin is required for cell proliferation
Early reports described that in proliferation-arrested rat liver cells,
which were shifted from a medium containing low to a high Ca2+ con-
centration, DNA synthesis was initiated and that this process was
inhibited by CaM antagonists and an anti-CaM antibody. The effect
was reverted upon addition of exogenous CaM [128,129]. This early
observation underscores the positive role of CaM facilitating entry in
the S phase of the cell cycle; but most intriguingly the observed effects
of the CaM-antibody and exogenous CaM hinted to the possibility of
an extracellular action of CaM. The signaling function of extracellular
CaM in plant cells controlling among other functions cell proliferation
has beenwell documented, for example in [130]. InDictyostelium, extra-
cellular CaM binds to a speciﬁc CaM-binding protein located within the
slime sheath and negatively regulates cell proliferation [131]. The
presence of CaM in different human body ﬂuids including serum, most
likely derived from platelets at least in part, has been reported [132],
and extracellular CaM appeared to stimulate DNA synthesis in murine
melanoma cells [133] and human leukemia cells [134,135]. In addition,
the presence of a CaM-like activity was suggested to stimulate the pro-
liferation of human umbilical vein endothelial cells by an autocrine
mechanism [136]. However, these results are highly controversial, as
given the acidic nature of CaM, the artefactual interaction of this protein
with the ligand-binding pocket of mitogenic receptors or other non-
relevant targets at the plasma membrane and/or CaM internalization
via pinocytosis cannot be excluded. Therefore, these uncertainties cast
serious doubts on the physiological role if any of extracellular CaM in
animal tissues.
Viral vector-driven overexpression of recombinant CaM in non-
transformedmammalian cells resulted in enhanced cell proliferation
by shortening the length of the G1 phase of the cell cycle and mitosis,
while downregulation of CaMwith antisense CaM RNAs arrested cell
cycling and proliferation in mouse epithelial non-transformed C127
cells derived from a mouse breast tumor [75,137–139]. Such experi-
ments are particularly difﬁcult to realize with high efﬁciency in
human and other mammalian cells, as three different CaM genes
code for a single highly conserved protein sequence [140]. Neverthe-
less, the role of CaM in tumor cell proliferation was ascertained by
using antisense RNA technology targeting the transcripts corre-
sponding to the three CaM genes. CaM downregulation inhibited
the proliferation of rat pheochromocytoma PC12 cells [141,142]
and rat glioblastoma C6 cells [143]. While overexpression of CaM
has a positive effect on the former cells [141] this is not the case in
the latter cell type [143], perhaps reﬂecting the excess of CaM in C6
cells.
In human T lymphocytes [144], several human lymphoblastoid cell
lines [145], and human teratoma cells [146], the mRNA level of CALM3
was higher than those of CALM1 and CALM2 during cell proliferation.
However, the transcripts of CALM1 and CALM2 appear to be more rele-
vant for the proliferation of rat pheochromocytoma PC12 cells than
the transcript of CALM3, as antisense-based suppression of the latter
had no signiﬁcant effect on the overall level of CaM expression [142].
This may suggest a differential expression of the three CaM genes
among species and/or cell types. Knocking out the CaM gene II in the
chicken bursa of Fabricius B lymphocyte neoplastic DT40 cell line that
reduced the expression of CaM by 60% only slightly decreased cell pro-
liferation but without altering the cell cycle proﬁle [147] indicating that
the ubiquitously expressed chicken CaM I gene is sufﬁcient for DT40
cells survival [148]. Recently, the essential role of CaM to sustain verte-
brate cell viability and proliferation was demonstrated using condition-
al CaM-knockout DT40 cells [149]. In addition, this cellular system
allowed the direct testing of the role of Ca2+ binding to CaM for verte-
brate cell proliferation by the expression of CaMmutants with impaired
capacity to bind Ca2+ to one or more of its four Ca2+-binding sites after
suppressing endogenous wild type CaM expression. Single Ca2+ bind-
ing site inactivation had no measurable effect on cell proliferation
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dramatically when sites III and IV were inactivated [149].
3.3. Calmodulin levels during cell proliferation
During exponential growth of Chinese hamster ovary (CHO)-K1 cells
the concentration of CaM was shown to progressively increase due to
the enhanced transcription of the CaM genes, and reached high levels
at the G1/S transition. The CaM level remained high during the ensuing
progression of the cell cycle and reached a maximum at the late G2 or
early M phases, decreasing thereafter when cells abandon the plateau
phase [150–152] (Fig. 4). A similar phenomenon was evident in a
hepatoma cell line in vitro and in the derived tumors developed in vivo
[153], in promyelocytic leukemia cells [154], and in chemically trans-
formed ﬁbroblasts [155]. Moreover, CaM levels and the corresponding
mRNAs also increased before cell replication during the regeneration
of rat liver after partial hepatectomy [156]. Protein kinase C (PKC) ap-
pears to regulate the expression of CaM during growth of normal rat
kidney cells [157].
The positive action of CaM on cell proliferation was demonstrated
in vivo by the targeted overexpression of CaM in the heart of transgenic
mice. CaM induced enhanced proliferation of cardiomyocytes with the
occurrence of a high number of polyploid cells, and the subsequent
development of ventricular hypertrophy, a phenomenon that was
reversed by turning off the ectopic expression of CaM [158,159]. In
this context, tumor necrosis factor-α (TNF-α) has been shown to induce
hypertrophy in neonatal cardiomyocytes by a mechanism implicating
both CaMK-II and CaN [160], possibly explaining at least in part the
mechanistic action of CaM in this process, which is further described
in Section 4. The changes in CaM levels during the different phases of
the cell cycle appear to be evolutionarily conserved as it also occurs in
protozoa, see for example [161].
In agreement with the above described observations, the action
of CaM antagonists in non-tumor cells, such as the CHO-K1 cells
[151,162], or in tumorigenic cells, such as avian sarcoma virus (ASV)-
transformed kidney cells [163], melanoma B16 cells [164] or human
breast cancer MCF-7 cells [165], is due to an arrest of the cell cycle atFig. 4.Calmodulin levels during cell cycle progression. The scheme depicts the increment of calm
of cell cycle arrest by CaM antagonists added at the indicated phases.the G1 phase, indicative of the prominent role that CaM plays at the
G1/S transition. However, when the CaM antagonist was added much
later, during the S phase, the cell cycle was arrested at the late G2 or
early M phases [150], further pointing to the involvement of CaM in
later phases of the cell cycle (Fig. 4).3.4. Subcellular localization of calmodulin during cell proliferation
Not surprisingly, due to its multiple functions CaM is normally
located in many cellular compartments including the cytosol, attached
tomembranes, inside the nucleus, and in different organelles, as demon-
strated by sub-cellular fractionation and by expressing ﬂuorescently-
labeled CaM species in cultured living cells. Early studies performed in
mammalian cells indicated a dynamic localization of CaM during cell di-
vision, moving from the cytosol to the nucleus in preparation for cell di-
vision, and attaching to the centrioles and the mitotic spindle during
mitosis [166–168]. In sea urchin, it was demonstrated that CaMwas pro-
gressively accumulated inside the nucleus when cells approach mitosis
and this nuclear localization could be blocked by a cell-permeable CaM
inhibitory peptide [169]. Similarly, in HeLa cells CaM was shown to be
mostly concentrated in the cytosol during the G1 phase and to move to
the nucleus when cells entered the S phase, reaching high levels at the
G2 phase, and thereafter during mitosis concentrate at the polar regions
of the mitotic spindle [170,171]. CaM was also co-localized with the as-
tral microtubules during inter-phase, as observed in sea urchin zygotes
when approaching mitosis [169]. Furthermore, CaM participated in the
lysis of the nuclearmembrane, distributing thereafter to the polar region
of the mitotic spindle, and was shown to be involved in chromatin con-
densation both in sea urchin and vertebrate cells [169–171]. The targeted
localization of CaM to different subcellular sites duringmitosis has a dual
nature, as Ca2+-dependent and Ca2+-independent mechanisms are op-
erative [169]. In addition, targeted inhibition of nuclear CaMby a peptide
derived from the CaM-binding domain (CaM-BD) of myosin light chain
kinase (MLCK) totally prevented the entry in S phase of COS-7 cells
[172]. As an example, Fig. 5 shows the dynamic distribution of green
ﬂuorescent protein (GFP)-CaM at different structures during mitosis,odulin (CaM) expression at the different phases of the cell cycle; and the twomajor points
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Fig. 5. Dynamic distribution of calmodulin duringmitosis and the effect of W-7 in HeLa cells. (Top) The spatial-temporal distribution of CaM and microtubules in the identical cell during
metaphase (A and D) anaphase (B and E) and telophase (C and F). The distribution pattern of the GFP-CaM fusion proteinwasmonitored (A–C), andmicrotubuleswere immunostained in
the ﬁxed cells (D–F). The central spindlewas assembled after metaphase/anaphase transition (arrow), while ﬁber-like distributed CaMwas found in central spindle regions (arrowhead).
Bar: 10 μm. (Bottom) Comparison of the central spindle microtubules of W-7 treated and untreated cells. The quantity of the central spindle microtubules and poles inW-7 treated cells
was decreased (H) compared to the normal cells with their well-organized central spindle microtubules (G). Bar: 10 μm.
Reproduced with minor changes from Ref. [347].
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the central spindle and poles.
3.5. Calmodulin targets involved in cell proliferation
3.5.1. Calmodulin-regulated growth factor receptors and signaling pathways
Proliferation signals are often initiated upon the ligand-dependent
activation of receptors located at the cell surface. Several tyrosine kinase
receptors are known to be CaM-binding proteins including the epider-
mal growth factor receptor (EGFR) [173–175], the related erythroblastic
leukemia viral oncogene homologue 2 product (ErbB2) [176,177], the
nerve growth factor receptor A (TrkA) [178], and the insulin receptor
[179], all playing prominent roles in cell proliferation (Fig. 6).
It has been demonstrated that the Ca2+/CaM complex binds to the
cytosolic juxtamembrane region of the EGFR modulating its tyrosine
kinase activity (reviewed in Ref. [175]). The functional importance of
the cytosolic juxtamembrane region of the EGFR, containing the CaM-
BD, during the ligand-dependent activation of the receptor following
an asymmetric allosteric model has been corroborated [180–182].
Recently, by using conditional CaM-knockout DT40 cells it was demon-
strated that CaM participates in the ligand-dependent activation of theEGFR [183]. In addition, CaMK-II phosphorylates Ser1046/Ser1047 in
the EGFR downregulating its tyrosine kinase activity and its internaliza-
tion [184]. Interestingly, it has been shown that a peptide comprising
the CaM-BD of the EGFR (Arg645–Arg662), conjugated to a human
immunodeﬁciency virus (HIV) transactivator of transcription (Tat)
sequence (HIV Tat 49–58) used to facilitate its cellular entry, inhibited
the EGFR and exhibited anti-cancer activity when tested in a variety
of tumor cells [185]. Similarly, a modiﬁed EGFR CaM-BD peptide
(Arg651-Leu658) in which Thr654 was replaced by a cysteine to intro-
duce PKC inhibitory properties [186], tagged with the hydrophobic sig-
nal sequence of the Kaposi ﬁbroblast growth factor (FGF) to allow cell
entry, also inhibited the EGFR and arrested cell proliferation [187].
Ca2+/CaM and apo-CaM both bind to the ErbB2 receptor at nearby
sites in the cytosolic juxtamembrane segment modulating receptor
activity and signaling [176,177]. The high-afﬁnity CaM-BD present in
EGFR/ErbB1, ErbB2, and ErbB4 is not well conserved in ErbB3, which
lacks intrinsic tyrosine kinase activity and exhibits lower CaM afﬁnity
[176,188,189].
The regulatory role of CaM on EGFR also includes its action on the
transactivation of the receptor mediated by PKC [190], the intracellular
trafﬁc of the ligand-bound receptor once it is internalized [191,192], and
Fig. 6.Action of calmodulin on tyrosine kinase receptors and some signaling pathways implicated in cell proliferation. The schemedepicts the binding of calmodulin (CaM) to the following
tyrosine kinase receptors: epidermal growth factor receptor (EGFR)/ErbB1, its related familymember ErbB2, thenerve growth factor receptor A (TrkA), and the insulin receptor (InsR). The
binding and activation of the non-receptor tyrosine kinase c-Src by CaM, and the binding and inhibitory action of CaM on K-Ras are also shown. The scheme also shows the stimulatory
(blue arrows) and inhibitory (red striped arrows) actions of phosphorylation of diverse target systems by CaM-dependent protein kinase II (CaMK-II), and the eventual generation of cell
proliferation signals (green arrows). ERK1/2, extracellular regulated kinases 1/2; IRS1/2, insulin receptor substrates 1/2; MEK1/2, mitogen-activated protein kinase kinases 1/2.
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CaM binding to and down-regulation of K-Ras, but not of H-Ras or
N-Ras, preventing its phosphorylation by PKC [193–195], and the
modulation of the mitogen-activated protein kinase (MAPK) pathway
at different points including the kinase Raf-1 (reviewed in Ref. [196]).
Other Ras-related GTP-binding proteins, which are under the control
of CaM are Kir and Gem. The latter protein has been shown to be in-
volved in growth regulation, as its downregulation prevented the prolif-
eration of mouse 3T3 ﬁbroblasts [197]. A peptide corresponding to the
CaMbinding domain of Kir/Gemwas found to bind CaMwith high afﬁn-
ity, and the full length Kir/Gem proteins bind CaM in a Ca2+-dependent
fashion as analyzed by a newly developed protein overlay technique
(Far-Western blotting) to visualize CaM-binding proteins [198]. In addi-
tion, CaM binding to Kir/Gem inhibited its GTP-binding activity indicat-
ing a direct regulatory function of CaM [199].
The CaMKK/CaMK-I system regulates the MAPK/extracellular
regulated kinase (ERK) pathway stimulating cell proliferation; see
for example [200] (reviewed in Ref. [201]). CaMK-II can be activated
by different mitogenic factors, e.g. platelet-derived growth factor
(PDGF) [202] or tumor/transforming growth factor-β (TGF-β) [203]
which induces the proliferation of hepatic stellate cells among
other cell types [204–207]. In vascular smooth muscle cells it was
demonstrated that CaMK-II associates with ERK facilitating the phos-
phorylation of both kinases via Raf-1 and the nuclear localization of
CaMK-II [207]. Mechanistically, it has been shown that CaMK-II
negatively regulates the levels of p21Cip1/Waf1 in lymphoblasts
via the MAPK(ERK1/2) pathway by inducing the phosphorylation
of the transcription factor Forkhead box O3a (Foxo3a). This isfollowed by the exit of CaMK-II from the nucleus to the cytosol and
its eventual degradation by a murine double minute protein 2
(MDM2)-mediated pathway, processes that appear to be defective
in lymphoblasts from Alzheimer's disease patients diminishing
entry in apoptosis (see also Section 4) [208]. Moreover, the interac-
tion of CaM with the putative guanine exchange factor β-PIX (β-
p21-activated kinase interacting exchange factor), and its associa-
tion with the E3 ubiquitin ligase c-Cbl (Casitas B-cell lymphoma
protein), might also regulate the degradation of ErbB receptors as
well as other tyrosine kinase receptors [209].
Both CaM and Janus kinase 2 (Jak2) control the activation of the
Na+/H+ exchanger (NHE) by the EGFR and other mitogenic receptors
through amechanism involving the phosphorylation of CaM at tyrosine
residues [210,211]. The binding of CaM to NHE has been ascertained, as
the crystallographic structure of its regulatory region in complex with
Ca2+/CaMwas recently determined [212]. Interestingly, the high prolif-
eration rate of lymphoblasts isolated from Alzheimer's disease patients,
as compared to those of healthy donors, appears to be mediated by the
CaM-dependent activation of NHE leading to intracellular alkalinization
[213]. This might also be relevant for cancer biology, as NHE activation
has been shown to play a signiﬁcant role in supporting proliferation of
tumor cells, e.g. bladder carcinoma cells [214].
Overall, these observations demonstrate that the regulatory role of
CaM in controlling cell proliferation involves the regulation of keymito-
genic receptors including the ErbB family and their downstream signal-
ing pathways (reviewed in Ref. [175]), as well as cytosolic membrane-
attached tyrosine kinases such as Src (Fig. 6). This is highly relevant
for tumor cell biology, as these receptors along with non-receptor
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tumors either due to gene duplication, enhanced expression, the ap-
pearance of point mutations, and/or constitutively active truncated
forms. Nevertheless, no mutations affecting the CaM-BD of the EGFR
in human astrocytic gliomas (89 cases), where altered expression and
high rate of mutations of this receptor are very common, were found
so far, which highlights the functional importance of this site
[215,216]. The CaM-like domain (CaM-LD) of the EGFR is an acidic
region that has been suggested to interact with the CaM-BD as it has a
sequence resembling CaM (reviewed in Refs. [175,188]). The CaM-LD
is located in the CAIN domain, distal of the tyrosine kinase catalytic
site, which is presumably involved in Ca2+ mobilization and receptor
internalization [217]. In-frame tandem duplication of exons 18–25 of
the EGFR in human gliomas has been shown to result in an aberrant
receptor with two CaM-LDs [215,216].
3.5.2. Calmodulin-dependent kinases and phosphatases
Manymechanisms of CaM action in cell proliferation and the control
of the cell cycle are mediated by CaM-dependent phosphorylation/
dephosphorylation events (reviewed in Refs. [78,218–220]). The best-
studied kinases involved in these processes are the multifunctional
CaM-dependent protein kinases (CaMKs)-I/II/IV (reviewed in Refs.
[221–224]); the distinct and more substrate-restricted CaMK-III [225];
and the upstream CaM-dependent kinase kinase (CaMKK) that activate
CaMK-I/IV (reviewed in Refs. [220,226,227]). The roles of these CaMKs
and other relevant CaM-regulated kinases in the control of cell prolifer-
ation are presented in Table 2.
The pharmacological inhibition of CaM-dependent kinases
[206,228–231], or their downregulation by small interfering RNA
(siRNA) [232,233], results in the inhibition of proliferation of different
cell types, particularly arresting the cell cycle at the G1/S transition
[228,229], or at the G2/M transition increasing in this manner polyploi-
dy [232]. In contrast, the expression of a constitutively active Ca2+-Table 2
Roles of calmodulin-regulated kinases in cell proliferation.
CaM-kinase Selected comments References
CaMK-I Controls the cell cycle (G0/G1) [221–224]a
CaMK-II Activates the MAPK pathway
Controls the cell cycle (G1/S and G2/M)
[221–224]a
CaMK-III Phosphorylates eEF2 during active cell
proliferation
[225]a
[632]
CaMK-IV Controls cell proliferation phosphorylating
transcription factors (Sp1, CREB, ATF1)
[221–224]a
[292,566]
CaMKK Controls cell proliferation by
phosphorylating CaMK-I/IV
[220,226,227]a
CASK Contains an N-terminal CaMK domain
Negatively regulates the cell cycle
upregulating p21Cip1/Waf1
[633,634]
DAPK Activates cell growth and protein synthesis
by phosphorylation of ribosomal protein
S6 via the EGFR/MAPK(ERK)/DAPK pathway
[635]a
PNCK Closely related to CaMK-I. Downregulated
upon entry in cell proliferation. Role in
mammary glands development
[240,636]
PYK2 Activated during zebraﬁsh oocyte fertilization
in preparation for cell division
[637,638]
WNK1/4 WNK1 activates the MAPK/ERK5 pathway
Mutation of the CaM-BD of WNK4 causes
pseudohypoaldosteronism type II
(Gordon's syndrome)
[639]a
[640]
ATF1, activating transcription factor 1; CaM, calmodulin; CaMK-I/IV, CaM-dependent pro-
tein kinases I/IV; CaMKK, CaM-dependent protein kinase kinase; CASK, CaM-dependent
serine protein kinase; CREB, cAMP response element-binding protein; DAPK, death-
associated protein kinase; ERK5, extracellular regulated kinase 5; MAPK, mitogen-
activated protein kinase; PNCK, pregnancy up-regulated non-ubiquitous calmodulin-
dependent kinase; PYK2, proline-rich tyrosine kinase 2; WNK1/4, with-no-lysine kinases
1/4.
a Review article.independent truncated-variant of CaMK-II in murine C127 cells arrests
the cell cycle at the G2 phase [234]. The Ca2+/CaM-dependent kinase
cascades also controls the functionality of many transcription factors
and transcriptional co-activators as well as co-repressors (reviewed in
Ref. [235] and discussed in detail in Section 3.5.5), which are differen-
tially responding to changes in amplitude and oscillating frequency of
the intracellular Ca2+ transients (reviewed in Ref. [236]).
CaM-dependent kinases appear to be very active in tumor cells,
where they contribute to accelerated cell proliferation. Examples are
CaMK-II in myeloid leukemia, glioma, and endometrial and thyroid car-
cinoma cells [237,238]; CaMK-III and CaMK-IV in glioma cells [228,237].
The enhanced activity of CaMK-IIγ in leukemia cells as compared to
normal cells appears to be controlled by the oncogenic fusion-protein
bcr-abl, resulting in the hyper-activation of several downstream signal-
ing routes involved in cell proliferation such as the MAPK, Jak/signal
transducers and activators of transcription (Stat) and glycogen synthase
kinase 3β (GSK3β)/β-catenin pathways [238]. In colon carcinoma cells
CaMK-II also interacts and activates mitogen-activated protein kinase
kinase 1 (MEK1) followed by the phosphorylation and subsequent deg-
radation of the Cdk inhibitor p27Kip1 promoting the progression of the S
phase and the G2/M transition [239]. In addition, PNCK is upregulated in
a subset of primary human breast cancers [240], and in clear-cell kidney
carcinomas its overexpression is associated with poor prognosis [241].
Among phosphatases the CaM-dependent calcineurin (CaN) plays a
central role in cell cycle regulation (reviewed in Refs. [242–245]), as it
controls the G0/G1 and G1/S transitions. Thus, inhibition of CaN with
cyclosporine A inhibits DNA replication in ﬁbroblasts stimulated with
basic ﬁbroblast growth factor [246]. The calcineurin B homologous
protein 2 enhances the proliferation of HeLa tumor cells [247], and the
α isoform of CaN appears to play an important role in small-cell lung
cancer by promoting not only cell proliferation but also metastatic
invasion [248].
Interestingly, small-cell lung carcinomas highly express the protein
tyrosine phosphatase receptor Z1 (PTPRZ1). Binding of its ligand
pleiotrophin inhibits PTPRZ1 activity thereby enhancing the phosphor-
ylation levels of CaM, which is concomitant with enhanced tumor pro-
gression [249]. The direct connection between phospho-Tyr-CaM
levels and tumor progression, however, is not yet established, besides
the fact that both the EGFR and Src kinase family members, all playing
prominent roles in cell proliferation and tumorigenesis, are known to
phosphorylate CaM (reviewed in Ref. [7]). This may be facilitated
because as previousy discussed, the EGFR (reviewed in Ref. [175]),
v-Src [250] and c-Src [251] are CaM-binding proteins.
A signiﬁcant interplay between CaM-dependent kinases and phos-
phatases exists as demonstrated using in vitro assay systems (Fig. 7).
CaM-dependent protein kinase phosphatase (CaMKP) dephosphory-
lates the multi-functional CaMKs-I/II/IV inducing their inactivation
[252–254] (reviewed in Ref. [255]), and reciprocally CaMKs-I/II
phosphorylate and activate CaMKP when assayed in vitro [256,257]. In
addition, CaMK-IV inactivates CaMKK,while its reactivation ismediated
by PP2A. This phosphatase also dephosphorylates CaMK-IV inducing its
inactivation (reviewed in Ref. [227]). The implication of CaMKP and its
nuclear isoform CaMKP-N in cell growth and viability has been demon-
strated in zebraﬁsh embryos in vivo, as its downregulation brings about
the initiation of apoptosis, speciﬁcally in brain and spinal cord neural
cells with the subsequent occurrence of developmental abnormalities
[258,259]. Of interest, the removal of the C-terminus from CaMKP-N
by an ubiquitin-proteasome-mediated proteolytic pathway favors its
translocation from the nucleus to the cytosol increasing its activity
toward phosphorylated CaMK-I and CaMK-II thereby inactivating
these kinases, while its unprocessed form inactivates nuclear CaMK-IV
at a much lower rate [260].
3.5.3. Calmodulin-regulated enzymes other than kinases/phosphatases
As brieﬂy mentioned in the Introduction, CaM was discovered as a
cyclic nucleotide PDE activator. PDE activitywas lost during puriﬁcation
Fig. 7. Crosstalk among calmodulin-dependent kinases and phosphatases. The scheme depicts the CaM-dependent kinase kinase (CaMKK), which phosphorylates (activates) CaMK-I and
CaMK-IV (at Thr200), while dephosphorylation of this residue by CaM-dependent protein kinase phosphatase (CaMKP) or protein phosphatase 2A (PP2A) induces its inactivation. Active
CaMK-IV retro-phosphorylates CaMKK (at Thr108) inducing its inhibition,while dephosphorylation of this residue by PP2A induces its reactivation. Active CaMK-I and CaMK-II both phos-
phorylate (activate) CaMKP, and this phosphatase dephosphorylates both kinases inducing its inhibition. Black arrows indicate activation and red Ts inhibition.
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PDE activator and named CaM [1,2]. After the initial identiﬁcation of
this ﬁrst CaM-binding/regulated enzyme many more followed, trailed
by all sorts of proteins without recognizable enzymatic activity but of
important physiological signiﬁcance.
An early report suggested the implication of the CaM-dependent cy-
clic nucleotide PDE in cell proliferation, as its expression and activity
was increased upon mitogenic stimulation of bovine peripheral lympho-
cytes with phytohemagglutinin (PHA) [261]. The isoform 1A of PDE pref-
erentially hydrolyzes cGMPandplays a positive role in the proliferation of
vascular smoothmuscle cells upon its localization in the nucleus. Blocking
its activity by chemical agents or downregulating its expression by siRNA
induces an increase in intracellular cGMP. This was shown to lead to a
proliferative arrest of cells at the G1 phase and the onset of apoptosis,
respectively mediated by the upregulation of p27Kip1 and the downregu-
lation of cyclin D1, as well as the activation of p53 [262]. Connected with
this observation, oscillating levels of CaM and cGMP may play a promi-
nent role during the progression of the cell cycle. In accordance, changes
in the activity of guanylate cyclase in the ciliate Tetrahymena mirror the
changing levels of CaM during this process [263].
Nitric oxide is a biphasic modulator of cell proliferation inducing
either activation or inhibition depending of its concentration (reviewed
in Refs. [264,265]). In this context, another CaM-dependent enzyme
that has been shown to participate in the control of cell proliferation is
the nitric oxide synthase (NOS). Meine et al. [266,267] have shown
that nitric oxide released from a chemical donor or by treating neuronal
tumor cells with interleukin (IL)-1β at low concentrations induces their
proliferation by activating theMAPK pathway. NOS inhibitors, aswell as
CaM andMAPK inhibitors, block the proliferation, suggesting that nitric
oxide produced by NOS is implicated in this process.3.5.4. Calmodulin-regulated adaptors and scaffolding proteins
The 14-3-3 proteins conform a family of adaptors involved in the reg-
ulation of signaling pathways in all eukaryotic cells by interactingwith an
extensive number of proteins by a phosphorylation-dependent manner.
This includes among many others, diverse kinases as for example Raf-1,
Cdks, Wee1; phosphatases such as cdc25; and regulatory Cdk inhibitory
proteins such as p21Cip1/Waf1, all of them implicated in cell proliferation;
as well as proteins controlling apoptosis such as Bcl-2-associated death
promoter (Bad), Bcl-2-associated X protein (Bax) and the transcription
factor Foxo (reviewed in Ref. [268]). CaM has been shown to directly in-
teractwith 14-3-3ε in a Ca2+-dependentmanner. Thismechanism repre-
sents another way by which CaM may control cell proliferation [269].
Moreover, it is known that 14-3-3 proteins play an important role in tu-
morigenesis [270–272]. In addition, 14-3-3 negatively regulates CaMKKα
when this kinase is phosphorylated by protein kinase A (PKA) in vitro and
in transfected HEK293 cells [273,274].
Growth factor receptor boundprotein 7 (Grb7), togetherwithGrb10
andGrb14, belongs to a family ofmammalian adaptor proteins phyloge-
netically related to the Caenorhabditis elegans protein Mig10 implicated
in embryonic neuronal cell migration [275,276]. These adaptors trans-
mit signals from receptor and non-receptor tyrosine kinases and other
tyrosine-phosphorylated proteins after binding to phospho-tyrosine
residues via the SH2 domain located at their C-terminus [277,278].
Grb7 is a Ca2+-dependent CaM-binding protein containing a CaM-BD
site in the proximal region of its PH domain [279]. Grb7 is involved in
cell migration processes [277,278], but also plays a major role in cell
proliferation [187,280,281], tumor growth and tumor-associated angio-
genesis [279,281].
Another scaffold protein that binds CaM is the IQ-containing Ras
GTPase-activating-like protein 1 (IQGAP1) [282,283], which is involved
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control of cell proliferation, cell–cell adhesion, β-catenin-mediated
transcriptional events, tumorigenesis and metastasis (reviewed in
Ref. [284]). The interaction of CaM with IQGAP1 occurs in a Ca2+-
dependent and -independent manner at their four IQ motifs located in
tandem in its central region [282], and in addition interacts in a Ca2+-
dependent manner at its calponin homology domain located in its N-
terminus [283]. A-kinase anchor protein 12 (AKAP12) is a scaffolding
protein that appears to suppress metastasis. Its downregulation, fre-
quently occurring inmanyhuman cancers, results in tumor progression.
AKAP12 interacts with some G protein-coupled receptors, several
kinases (PKC, PKA, Src), other enzymes such as PDE, and structural as
well as signaling proteins including CaM. In thismanner AKAP12 partic-
ipates in mitogenic signaling and the remodeling of the cytoskeleton
during cell migration, processes associated to oncogenic progression
(reviewed in Ref. [285]). The adaptor protein denoted Fas-associated
proteinwith death domain (FADD), involved in apoptosis by connecting
death receptors to the initiating caspases-8/10 forming the death-
inducing signaling complex (DISC) (discussed further in Section 4),
has been found to bind CaM in a Ca2+-dependent manner. FADD is
also implicated in autophagic cell death, proliferation and cell cycle con-
trol, among other functions [286].
3.5.5. Calmodulin-regulated transcription factors
Cell proliferation requires the coordinated activation or silencing of
multiple genes at speciﬁc time points. CaM directly regulates these pro-
cesses by binding to transcriptional regulators and most importantly
through CaM-dependent phosphorylation/dephosphorylation events
mediated by CaMKs cascades and CaN, thus modulating the activity of
transcriptional factors that are expressed in a cell cycle speciﬁc fashion
(reviewed in Refs. [244,287,288]). This has been observed for example
with the expression of CaM-binding transcription activators 1/2
(CAMTA1/2) during cardiac growth and tumor suppression (reviewed
in Ref. [289]). CAMTA1 controls the S and M phases of the cell cycle in
neuroblastoma SK-N-SH cells [290]. CaM also binds to two different iso-
forms of the transcription factor C/EBP-β (CCAAT/enhancer binding
protein-β), denoted C/EBP-β-LAP (liver activator protein) and C/EBP-
β-LIP (liver inhibitor protein), preventing the growth promoting activi-
ty of the latter. C/EBP-β-LIP controls the transcription of genes required
for the S phase by preventing the repressing action of the retinoblasto-
ma protein (pRb) on the E2F promoter and disrupting the E2F1–pRb
complex [291]. The pRb-regulated transcription factor Sp1 is also
under the control of CaM due to its phosphorylation by both CaMK-II
and CaMK-IV [292]. Furthermore, inhibition of CaM in human ﬁbrosar-
coma cells enhances the expression of early growth response protein 1
(Egr-1), repressing cell proliferation by a mechanism involving the
control of the Ras/MAPK/Elk-1 (E twenty six-like transcription factor
1) pathway exerted by CaMK-II and CaN [293].
Activation of CaN by the Ca2+/CaM complex results in the dephos-
phorylation of the transcription factor denoted nuclear factor of activat-
ed T cells (NFAT) and its translocation to the nucleus. In cooperation
with AP-1 (Fos/Jun) NFAT positively regulates the transcription of
multiple genes or induces gene silencing by interacting with histone
deacetylases (reviewed in Refs. [294,295]). The CaN/NFAT pathway
has been shown to control the growth of a variety of cells including
cardiomyocytes [296], pancreatic β cells [297], vascular smooth muscle
cells [298,299] and hepatocellular carcinoma cells [300] among others.
Deregulation of this signaling route plays an important role in tumori-
genesis (reviewed in Refs. [301–303]). The CaN/NFAT pathway seems
to have diverse and cell type speciﬁc effects. In T lymphocytes and Jurkat
cells CaN/NFAT negatively controls the expression of Cdk4 [304],
required for the G1/S transition. However, in vascular smooth muscle
cells CaN/NFAT induces the expression of cyclin A [305], required for
the progression of the S and G2/M phases. Furthermore, the reduced
growth rate of leukemic HL-60 cells induced by retinoic acid-mediated
differentiation appears to be due to increased CaN expression andactivity [306]. Transcriptional processes regulated by CaM through
phosphorylation and dephosphorylation events catalyzed, respectively,
by CaMK-II and CaN, have been described as well in normal tissue
growth and development, as for example in skeletal muscle (reviewed
in Ref. [307]). In addition, CaM regulates the nuclear entry of the tran-
scription factors sex-determining region on the Y chromosome (SRY)
and Sry-related high-mobility-box (SOX) family by binding to one of
its nuclear localization sequences. This is an important event for gonadal
cells terminal differentiation (reviewed in Ref. [308]).
3.5.6. Calmodulin-regulated cell cycle proteins
In addition to the CaM-regulated kinases and phosphatases control-
ling the cell cycle, there are other proteins participating in the cell cycle
machinery that directly bind CaM. One example is Cdk5, an atypical Cdk
familymember negatively controlling the cell cycle arresting the cells at
Go by stabilizing the Cdk2/cyclins E/A inhibitor p27Kip1 [309]. Cdk5 has
been shown to be a CaM-binding protein inDictyostelium [310], howev-
er information on Cdk5/CaM interaction in vertebrate cells is not
yet available to our knowledge. The neural Cdk5 activator p35 is a
CaM-binding protein [311]. Cyclin E1, a Cdk2 partner, is another
CaM-binding protein that controls the G1/S transition [312,313]. The
CaM interacting 14-3-3 proteins e.g. 14-3-3ε [269], described in
Section 3.5.4, control the G1/S and G2/M transitions. They sequester
key cell cycle components such as the Cdk2/cyclin E and Cdk1(cdc2)/
cyclin B complexes and the phosphatases cdc25A/B/C in the cytosol,
preventing progression of the cell cycle, or sequestering phospho-
p27Kip1 facilitating its progression [314]. The C-terminal domain of
the Cdk4/cyclin D inhibitor p21Cip1/Waf1 directly interacts with CaM in
a Ca2+-dependent manner [315,316], facilitating its nuclear entry by
preventing its phosphorylation by PKC [315,317], and therefore control-
ling the G1/S transition.
3.6. Calmodulin and the control of speciﬁc cell cycle phases
3.6.1. The G0/G1 transition
Several CaM-dependent systems are involed in the regulation of the
G0/G1 transition (Fig. 8). CaN via NFAT appears to favor the expression
of cyclin D at early G1 but paradoxically repressing the Cdk4 promoter
and inactivating this kinase by dephosphorylation, hence regulating
the cyclin D/Cdk4 complex in mammalian cells (reviewed in Refs.
[78,318]). CaMK-I more likely than CaMK-II may participate in G1
progression (reviewed in Ref. [78]). The Ca2+-independent activity of
CaMK-II and the Ca2+-dependent activity of CaN both increase when
vascular smooth muscle cells transit from G0 to G1/S [319].
3.6.2. The G1/S transition
The G1/S transition is one of the most critical checkpoints of the cell
cycle where CaM controls a variety of systems (Fig. 8). The Ca2+/CaM
complex regulates the phosphorylation of pRb at an early stage of the
cell cycle. CaM antagonists added at an early time after stimulation
with growth factors inhibited this process in a variety of cells. This
did not happen when the inhibitors are added at a later time point
[320,321] (see also Fig. 4). Mechanistically, CaM antagonist-induced
arrest of the cell cycle in normal rat kidney cells at the G1/S transition
appears to be due to the inhibition of Cdk4 and Cdk2, as this results in
pRb hypophosphorylation [321]. The association of CaM with Cdk4/
cyclin D1 was proposed to be mediated by heat shock protein 90
(Hsp90) [321], which was earlier shown to interact with CaM [322]. In
WI-38 ﬁbroblasts CaN induced the expression of cyclin D1 at the early
G1 phase [323]. On the other hand, it inhibits Cdk4, but not Cdk6 or
Cdk2 in Jurkat cells, by removing the phosphate introduced by cyclin ac-
tivating kinase (CAK), that is the activating kinase of Cdk4, and therefore
negatively controls theG1/S transition [304,324]. The heat shockprotein
70 (Hsp70) has a CaM-bindingmotif [325]. In the nucleus of mammali-
an cells the interaction of Hsp70 with CaM during the S phase partici-
pates in the arrest of cell cycle at this point inducing apoptosis [326].
Fig. 8. Calmodulin-controlled systems in cell cycle progression. The scheme depicts major calmodulin-dependent systems controlling the different phases of the cell cycle. CaM, calmod-
ulin; CaMK-I/II, CaM-dependent protein kinases I/II; CaN, calcineurin; Cdk1/2, cyclin-dependent kinases 1 and 2; Cyc B/E, cyclins B and E; Plk1, Polo-like kinase 1.
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G1/S transition is its interaction with cyclin E1 leading to activation of
the Cdk2/cyclin E complex in a Ca2+-dependent manner [312,313]. In
this context, an inhibitory peptide based on the CaM-BD of cyclin E
disrupted the interaction of this cyclin with Cdk2 and arrested the cell
cycle at the G1/S transition in primary mouse aortic smooth muscle
cells [327]. Moreover, the CaM-binding adaptor protein 14-3-3 inhibits
the G1/S transition by sequestering the Cdk2/cyclin E complex in the
cytoplasm (reviewed in Ref. [314]).
CaMK-I positively controls cell proliferation, as its downregulation
with siRNA inhibited cell growth and diminished the expression of c-
Fos [233]. CaMK-I also appears to participate in Cdk4 activation facilitat-
ing the Cdk4/cyclin D assembly. The pharmacological inhibition of this
kinase with KN-93 or the overexpression of a dominant negative
kinase-null mutant induced the association of p21Cip/Waf1 and p27Kip1
with the Cdk4/cyclin D complex arresting the cell cycle at G1 in
human WI-38 ﬁbroblasts [328]. On the other hand, direct binding of
CaM to p21Cip/Waf1 in a variety of cells (NRK, NIH3T3, COS7) facilitated
the entry of this Cdk inhibitor into the nucleus by preventing its phos-
phorylation by PKC, that otherwise will block its nuclear localization
as shown in NRK cells [315,317] (reviewed in Ref. [313]). In breast car-
cinoma MCF-7 cells, the inhibition of the CaMKK/CaMK-I pathway also
resulted in the arrest of the cell cycle at the G1 phase, accompanied
by the downregulation of cyclin D1 and pRb hypophosphorylation
[329]. In normal and tumor lung epithelial cells, the ubiquitin E3 ligase
element F-box protein 12 (Fbxl12) participates in G1 arrest by inducing
the degradation of CaMK-I [330].
The activation of CaMK-II and its downstream MAPK pathway can
result from signals arriving from the tyrosine kinase receptor RET, hy-
peractive B-Raf or Ras mutated forms, as demonstrated in thyroid
carcinoma cells [331]. In colon cancer cells CaM inhibition by different
curcumin derivatives induced a sustained phosphorylation of ERK1/2,
but most signiﬁcantly an upregulation of p21Cip1/Waf1, and hence
arresting the cell cycle [332,333]. A similar effect on ERK2 activationand upregulation of p21Cip1/Waf1 upon inhibition of CaM with W-13
was observed in NIH3T3 ﬁbroblasts [334]. This is in agreement with
studies done using CaMK-IIδ−/− transgenicmice, and their derived vas-
cular smoothmuscle cells, where decreased expression of cyclins E and
D1, lower Cdk2 and Cdk4 activity, and upregulation of p21Cip1/Waf1 were
detected, while the opposite was found in control wild type cells [335].
It was also found that the elevated expression of p21Cip1/Waf1 in these
cells was due to the upregulation of the p53 pathway [335]. Neverthe-
less, CaMK-II may also negatively regulate the G1/S transition by
phosphorylating the large subunit of the replication factor C thus
preventing DNA replication [336]. Overall, this emphasizes the occur-
rence of multiple and apparently conﬂicting CaM-regulated control
mechanisms acting at the G1/S transition, which may operate in a cell-
speciﬁc fashion.
3.6.3. The G2/M transition
CaM controls the G2/M transition via CaMK-II (Fig. 8). Inhibition of
CaM induces the downregulation of cyclin A and Cdk1(cdc2) [321].
The Cdk1(cdc2)/cyclin B complex is able to phosphorylate and activate
the phosphatase cdc25C by a positive auto-activation loop, further re-
leasing the inhibitory Wee1-mediated phosphorylation of Thr14/
Tyr15 in remaining Cdk1(cdc2) molecules. The activating phosphoryla-
tion of cdc25C can initially be catalyzed by CaMK-II, hence facilitating
the further activation of the Cdk1(cdc2)/cyclin B complex during the
G2/M transition as demonstrated in HeLa cells [337]. Polo-like kinase 1
(Plk1) is also an important regulator of the G2/M transition. Recently,
this kinase was shown to bind and to be activated by CaM when cells
are transiting from G2 toM phase stimulating thereby the phosphoryla-
tion of cdc25C [338]. When human erythroid leukemia cells were
subjected to ionizing radiation arresting the cell cycle at G2/M, the
observed activation of CaMK-II was preceded by enhanced Ca2+ entry
controlled by voltage-gated K+ channels (Fig. 1), followed by the inac-
tivation of both cdc25B and Cdk1(cdc2) [339]. The sequestration of
the phosphatases cdc25B and the Cdk1(cdc2)/cyclin B complex in the
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Ref. [314]).
3.6.4. The M phase and cytokinesis
CaM plays important roles during mitosis and cytokinesis, shifting
subcellular location during mitotic progression and acting on a series
of important targets, which regulate these processes. The potential
role of CaM duringmitosis can be studied by visualizing the localization
of ﬂuorescent CaM species, such as by expressing the chimera GFP-CaM
(see for example Refs. [170,171] and Fig. 5). Alternatively, CaM tagged
with a ﬂuorescent probe, such as RITC-CaM, TA-CaM or FL-CaM, can
be microinjected to study its functionality in living cells [63,166,168],
or localized in ﬁxed cells by electron microscopy and immunocyto-
chemistry using an antibody against performic acid-treated CaM [167].
The ﬂuorescence emitted by TA-CaM represents active Ca2+/CaM
bound to its targets while the ﬂuorescence emitted by FL-CaM is insen-
sitive to Ca2+ binding [63]. Bymeasuring the differential signals of both
ﬂuorescent CaM species it was demonstrated that active CaM is mostly
located in the nucleus in preparation for mitosis (interphase at G2 and
prophase). CaMwas also shown to be associated with the aster at inter-
phase; and during metaphase active CaM associated to the spindle, the
spindle poles, the astral microtubules and centrosomes, remaining at
this location during early anaphase but fading away thereafter [63]
(Fig. 9). A role of CaM in the mitotic spindle appears to be mediated
by CaMKK, which is, together with liver kinase B1 (LKB1), an upstream
kinase for the phosphorylation of AMP-activated protein kinase
(AMPK). AMPK in turn phosphorylates the downstream substrate myo-
sin regulatory light chain (MRLC) to achieve proper mitotic spindle ori-
entation [340]. The participation of CaMKKβ as the leading upstream
kinase of AMPK in LKB1-defﬁcient tumor cells was demonstrated by ac-
tivating this pathway by baicalin, a natural ﬂavonoid that prevents lipid
accumulation in the liver [341]. MLCK, a CaM-binding enzyme that may
have a species-speciﬁc role in these processes, was shown to be local-
ized in the cleavage furrow and may be phosphorylated by the kinase
Aurora B in mammalian cells during cytokinesis (reviewed in Ref.
[342]).
It has been suggested that CaM could participate in the shortening of
the interpolarmicrotubules and those associated to the kinetochores, par-
ticipating aswell in the assembly of chromosomes at themetaphase plate,
but CaM does not appear to participate in the shortening of the astral mi-
crotubules. Microinjection of Ca2+/CaM during early prometaphase
prolonged the time that the cells take to reach anaphase and therefore re-
tardedmitosis, an effect that was also observed with Ca2+ only, although
with lower efﬁciency [343]. On the other hand, antagonizing CaM with
W-7, calmidazolium or a phenothiazine-CaM adduct denoted CAPP1-
CaM inhibited metaphase progression [344]. An additional proposed
mechanism explaining the implication of CaM in the control of mitosis
is through binding to the centrosome-located Ca2+/CaM-activated kinase
Aurora A, thereby facilitating mitotic progression and cytokinesis. Inhibi-
tion of CaMon the other handwas shown to reduce the interaction of this
kinase with its activator neural precursor cell expressed developmentally
down-regulated protein 9 (Nedd9) preventing these processes [345]. Au-
rora B was also shown to interact with CaM, protecting this kinase from
ubiquitination by competing with the E3 ligase subunit F-box and
leucine-rich repeat protein 2 (Fbxl2) and thereby preventing destabiliza-
tion of chromosome segregation, the occurrence of multi-spindle
formation and tetraploidy [346].
CaM participates in cytokinesis by associating to the central spindle,
controlling themigration of the centrioles andmediating the formation
of the cleavage furrow, processes that can be prevented by W-7 treat-
ment, not only in vertebrate cells [347,348], but also in protozoa [349].
Along this line, down-regulation of CaM by antisense RNA technology
in Dictyostelium prevented completion of cytokinesis [350]. In Tetrahy-
mena, CaM was shown to act during cytokinesis by its Ca2+-
dependent interaction with an 85 kDa protein that participates in the
recruitment of G-actin to the cell division plane for the formation ofthe contractile ring responsible for the generation of the cleavage
furrow [349,351]. In early embryos of C. elegans downregulation of
CaM using RNA interference did not alter cytokinesis, even though it in-
duced minor defects in chromosomes segregation [352]. However, it
cannot be excluded that the residual (≈4%) CaM remaining after RNA
interference could be responsible for the apparent absence of major
effects of CaM during cytokinesis in this organism.
Several CaM-binding proteins with functions in cell cycle regulation
are also involved in cell death programs, one of them being FADD
(discussed in Section 4). Interestingly, when FADD regulates non-
apoptotic functions in HeLa cells controlling the cell cycle, the interac-
tion of CaM with this protein induced the co-localization of CaM
together with casein kinase I at the mitotic spindle during metaphase
and anaphase [286].
3.7. Cell cycle progression during egg fertilization
Fertilization of vertebrate eggs induces a rise in the cytosolic Ca2+
concentration mediated by a set of Ca2+ oscillations and propagating
waves, processes that are required to resume the proliferation of unfer-
tilized eggs previously arrested at meiotic metaphase II. Ca2+ release
from the endoplasmic reticulum and Ca2+ entry by the STIM1/Orai1
CaM-binding system play important roles in mammalian egg fertiliza-
tion (reviewed in Ref. [353]).
In Xenopus eggs the proteolytic degradation of cyclin B by the
ubiquitin-dependent pathway during exit from meiotic metaphase II
occurs after inactivation of the cytostatic factor c-mos and the M
phase-promoting factor by CaMK-II-mediated phosphorylation. This
was demonstrated either by inhibiting this kinase with speciﬁc inhibi-
tors or sequestering CaM by an inhibitory Ca2+/CaM-binding peptide
corresponding to the CaM-BD of MLCK, and conversely by activating
the process expressing a constitutively active form of CaMK-II
[354–356].
The translational control of cyclin B1 during cell cycle progression is
mediated by a complex formed by the protein denoted Maskin with
cytoplasmic polyadenylation element-binding protein (CPEB) and eu-
karyotic initiation factor 4E (eIF4E) among other factors [357]. In this
context, phosphorylation of Maskin by Cdk1(cdc2) allowed the transla-
tion of cyclin B1 mRNA, which is required for progression to the M
phase, while dephosphorylation of Maskin by CaN prevented cyclin B1
translation [358]. Upon a surge of Ca2+ during fertilization of Xenopus
eggs the activation of CaMK-II by Ca2+/CaMwas shown to lead to phos-
phorylation of the phosphatase cdc25C at Ser287 inhibiting its activity
thereby delaying reentry into the M phase [359]. A particular form of
CaMK-II denoted as cyk has been identiﬁed as a cyclin B2 kinase,
although phosphorylation of this cyclin does not appear to affect its
functionality [360]. CaMK-II also plays a role in the resumption of the
cell cycle in metaphase II-arrested mouse eggs [361]. This effect
was shown to be mediated by the single CaMK-II isoform γ3 in mouse
eggs [362]. In addition, phosphorylation of myosin-V by CaMK-II
prevented organelle transport along the actin microﬁlaments, such as
melanophores, duringmitosis in Xenopus eggs, as it released themolec-
ular motor from the organelle [363]. Furthermore, CaM was shown to
interact with the microtubule-associated protein ASPM (abnormal
spindle-like microcephaly-associated protein) during mitosis I in
mouse oocytes, thereby participating in the assembly of the spindle
during meiosis [364].
4. Calmodulin in programmed cell death
4.1. General comments and main players in programmed cell death related
to calmodulin signaling
Higher eukaryotes have developed a number of essential processes
leading ﬁnally to cell death. Failure of these processes often leads to dis-
eases including e.g. cancer. Understanding the molecular mechanisms
Fig. 9. Location of calmodulin during mitosis and cytokinesis. The scheme depicts the major points of localization of calmodulin (CaM) during the different phases of mitosis and cytoki-
nesis. The scheme also shows the location of Aurora A, and its activator neural precursor cell expressed developmentally down-regulated protein 9 (Nedd9), at the spindle poles during
metaphase and anaphase; and at the cleavage furrow, togetherwithmyosin light chain kinase (MLCK), during cytokinesis. The CaMKK/AMPK/MRLC cascade acting to attain proper spindle
orientation is also shown in metaphase. AMPK, AMP-activated protein kinase; CaMKK, CaM-dependent protein kinase kinase; MRLC, myosin regulatory light chain.
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has huge implications for the advances of novel therapies. Even though
distinct molecular pathways were delineated in the recent years, these
mechanisms are highly interconnected and players in the cell death
mechanisms often have other functions as well. Because of misconcep-
tions and confusions in the vocabulary of scientiﬁc reports dealing with
cell death the Nomenclature Committee on Cell Death (NCCD) has
proposed a classiﬁcation of death processes, which is mostly based on
morphological characteristics and recommended methods to describe
cell death pathways [365]. The basic categories of cell death are
described as apoptosis, autophagy, corniﬁcation and necrosis. All these
processes may occur in a programmed fashion. Later, based on the rap-
idly growing knowledge on molecular and functional features of cell
death, the NCCD published the molecular deﬁnitions of cell death
[366]. This functional classiﬁcation includes extrinsic apoptosis involv-
ing cell death receptors such as Fas (TNF receptor superfamily member
6) and related receptors, caspase-dependent or caspase-independent
intrinsic apoptosis involving mitochondria, regulated necrosis, autoph-
agic cell death and mitotic catastrophy. Of note, autophagy also plays
an important prosurvival role in the cell and this is why it will be
discussed separately in Section 5.
Transient elevation of Ca2+ provoked by the action of e.g. hormones,
chemical inhibitors such as thapsigargin, which blocks the endoplasmicreticulum Ca2+ uptake pump, and also cancer drugs has been shown to
induce apoptosis. On the other hand, Ca2+ signals appearing later dur-
ing the apoptotic process also seem to be important for the execution
of programmed cell death, and uptake of Ca2+ by mitochondria may
lead to permeability change and release of proapoptotic proteins
(reviewed in Ref. [85]). The Ca2+-activated protease calpain has been
shown to be a proapoptotic factor by its ability to cleave and activate
various proteins implicated in the apoptotic process including Bax and
Bid (BH3 interacting-domain death agonist) (reviewed in Ref. [367]).
As CaM is themain intracellular Ca2+ signalmediator protein and an
important factor of cell viability and proliferation it is not surprising that
its interactionwith target proteins and theirmodulationhas amajor im-
pact on cell death. In addition, because elevated intracellular Ca2+ can
have both growth promoting and also cell death-inducing conse-
quences, CaM regulates apoptotic processes both positively and nega-
tively (Fig. 10). CaM is involved in various ways in different types of
apoptotic processes including the activation of transcriptional programs
as shown e.g. in IL-2 deprivation-induced T-cell death that functionally
involves the CaM-binding protein neurogranin, also named RC3 [368].
Neurogranin, which is transcriptionally induced by IL-2, increases the
intracellular Ca2+ concentration leading to cell death by sequestering
CaM and stabilizing its Ca2+-free form thereby increasing intracellular
Ca2+.
Fig. 10. Calmodulin action on systems controlling apoptosis. The scheme depicts the major components participating in the extrinsic and intrinsic apoptotic pathways and the different
calmodulin (CaM)-dependent systems controlling apoptosis. Connections between the extrinsic and intrinsic pathways are also shown. AIF, apoptosis-inducing factor; Apaf-1, apoptotic
protease activating factor 1; Bad, Bcl-2-associated death promoter; Bak, Bcl-2 homologous antagonist; Bax, Bcl-2–associated X protein; Bcl-2, B-cell lymphoma 2 protein; Bcl-XL, B-cell
lymphoma-extra large protein; Bid, BH3 interacting-domain death agonist; CalpStat, calpastatin; CaMK-II/IV, CaM-dependent protein kinases II/IV; CaMKLK, CaM-dependent protein
kinase-like kinase; CaN, calcineurin; Cas3/6/7/8/9/10, caspases 3/6/7/8/9/10; c-FLIP, cellular FLICE-like inhibitory protein; cyt c, cytochrome c; DAPK1/2, death-associated protein kinases
1/2; DISC, death-inducing signaling complex; DR4/5, death receptors 4/5; EndoG, endonuclease G; ER, endoplasmic reticulum; FADD, Fas-associated protein with death domain; Fas
(CD95), TNF receptor superfamily member 6; FasL, Fas ligand; FKBP38, FK506-binding protein 38; IP3, inositol-1,4,5-trisphosphate; IP3R, IP3 receptor; prCas3/6/7/8/9/10, pro-caspases
3/6/7/8/9/10; TNFR, tumor necrosis factor-α receptor; TRAIL, TNF-related apoptosis-inducing ligand.
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CaM-dependent kinases and phosphatases. One CaM-dependent
serine/threonine protein kinase discovered in apoptosis research byKim-
chi and collaborators [369] is the CaM-dependent death-associated pro-
tein kinase (DAPK), and its related but shorter family member DRP-1
(reviewed in Refs. [370–374] A shorter spliced-variant of DRP-1 denoted
DRP-1β lacks, however, the CaM-bindingmotif [375]. The extensive liter-
ature on the function of DAPK and related proteins will not be discussed
in this chapter, as comprehensive review articles exist (reviewed in
Refs. [373,374,376]). CaMK-II has as well been intensively studied in the
context of cell death regulation during the recent years, particularly in
connection with death of normal and transformed neuronal, heart and
pancreatic cells, as well as a number of cancerous cells. An intriguing
study by Olofsson et al. [377] who screened 40 known apoptosis-
inducing chemicals for their site of action in connection with four impor-
tant apoptotic mediators including p53, activator protein 1 (AP1), NFAT
and nuclear factor κ-light-chain-enhancer of activated B cells (NFκB),
showed that Ca2+ was involved in most of the pathways in a late stage
and that CaM and CaMK-II play major roles in several Ca2+/CaMK-
dependent apoptosis-inducing pathways. The authors proposed that
Ca2+/CaM signaling might be involved in apoptotic pathways bysustained activation of c-Jun N-terminal kinase (JNK) through the func-
tion of CaMK-II [378]. The importance of CaM in apoptotic pathways is
highlighted also by the evolutionary conservation of CaM-dependent
cell deathpathways. One example is its participation in an apoptosis path-
way in Drosophila, where Reaper, which has similarity to vertebrate
Fas and the TNF-α receptor, has been shown to activate a Ca2+/CaM-
dependent signaling pathway ﬁnally leading to caspase activation and
death of cultured Drosophila S2 cells inducibly transfected with Reaper
[379]. Based on a complete inhibition of apoptosis by the CaM inhibitor
W-7 the authors suggested that CaM plays an essential role in Reaper-
induced apoptosis. However, a speciﬁc CaM-dependent pathway could
not be identiﬁed in this study.
Using the monocytic cell line U937 Wright and collaborators [380]
reported on a proapoptotic function of CaMK-II in signaling leading to
apoptosis induced by TNF-α and ultraviolet (UV) light. Both of these
apoptosis-inducing stimuli markedly increased the CaM-independent
activity of CaMK-II. Blocking CaMK-II activity by inhibitors of TNF-α-
and UV-induced apoptosis could also be shown in a variety of lympho-
ma cell lines. However, these inhibitors could not block Fas-induced ap-
optosis indicating that CaMK-II is not generally necessary for apoptosis
induction. The 24 kDa apoptotic serine protease (AP24), which induces
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the activity of CaMK-II in the used experimental system. CaMK-II activa-
tionwas shown to bemediated through the activity of caspases indicat-
ing that it acts downstream of caspases and upstream of the apoptotic
protease AP24.
CaMK-II seems to be important for endoplasmic reticulum (ER)
stress-induced apoptosis. ER stress is connected with increased cytosol-
ic Ca2+, which triggers a variety of processes. Importantly, increased
Ca2+ uptake into mitochondria may lead to apoptosis. Timmins et al.
[381] found that increased cytosolic Ca2+ as a consequence of ER stress
induces the expression of the Fas receptor (CD95) through the activity
of CaMK-IIγ and JNK. Mitochondria-mediated apoptosis was also de-
pendent on CaMK-IIγ as shown in the same article by loss of the mito-
chondrial membrane potential and cytochrome c release in a variety
of cells. Besides, CaMK-IIγ deﬁcientmice showed reducedmitochondri-
al dysfunction and apoptosis induced by ER stress as well as other
improvements of pathophysiological processes. This led the authors to
propose that CaMK-IIγ inhibitors may be used as drugs to prevent
ER-mediated apoptosis.
CaN is known to dephosphorylate the transcription factor NFAT,
which then translocates to the nucleus and activates gene transcription
(discussed in detail in Section 3.5.5). Overexpression of CaNwas shown
to lead to apoptosis in growth factor-deprived baby hamster kidney
BHK-21 ﬁbroblasts [382]. Well documented is the function of CaN in
dephophorylating Bad allowing its translocation to the mitochondria
and heterodimerization with the B-cell lymphoma-extra large protein
(Bcl-XL) [383]. In addition, CaN has been shown to be involved in
p53-induced cell death in cancer cells downstream of proline oxidase,
which produces proline-dependent reactive oxygen species (ROS)
followed by Ca2+ mobilization from intracellular pools and activation
of CaN [384].
4.2. Calmodulin in neuronal cell death
Extensive information exists on the function of CaMK-II in neuronal
tissue. This kinase is a central enzyme playing important roles in pre-
and post-synaptic functions, including neurotransmitter release, as
well as in the process of long-term potentiation. Early work indicated
that ischemia- or hyperthermia-induced neuronal damage leads to inhi-
bition of Ca2+-dependent phosphorylation mediated by CaMK-II,
suggesting that impaired CaMK-II activity may be important for the
development of ischemia-induced cell death in gerbils [385]. Amore re-
cent study by Uno and co-workers [386] indicated that CaMK-II activity
is connected with neuroprotection in the gerbil hippocampus where
CaMK-II is especially abundant. This study showed that under neuro-
protective conditions such as hypothermia the decrease in cytosolic
CaMK activity seen after ischemia is markedly reduced. Supporting
this ﬁnding Xu et al. [387] discovered that treatment of CA1 pyramidal
cells with subtoxic concentrations of N-methyl-D-aspartate (NMDA),
known to enhance neuronal cell survival in vivo and in vitro, involves
the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. They showed
that binding of CaM to the 85 kDa subunit of PI3K was enhanced by
this treatment, which leads to the activation of Akt. This indicated a
direct participation of CaM in this process.
An antiapoptotic function of CaMKs was found by McGinnis and
colleagues who reported that CaMK-IV was proteolytically cleaved by
caspase-3 in thapsigargin-induced apoptosis in human neuroblastoma
SH-SY5Y cells [388], and that inhibiting CaMK-II using KN-93 enhanced
Ca2+-induced apoptosis in the same cell line [389]. CaMK-IV also seems
to be an important player in neuronal cell survival as it phosphorylated
cAMP response element-binding protein (CREB) at Ser133 known to
be important for neuronal viability and overexpression of CaMK-IV
attenuated neuronal apoptosis in cerebellar granule neurons [390].
CaM-dependent protein kinase-like kinase (CaMKLK), an enzyme
with structural similarity to CaMK-IV, it was shown to be cleaved by
caspase activity, which accelerated apoptosis in NG108 cells [391].Overexpression of a non-cleavable mutant of CaMKLK protected from
apoptotic cell death indicating an active role of this kinase in the apo-
ptotic process. CaMK-IV also seems to protect from amyloid precursor
protein-induced neuronal cell death, which involves CaN and calpain
but is independent of caspase-3 and nucleosomal cleavage [392].
CaMmayprevent ischemic neuronal death throughCaMKK,which is
anupstream regulator of CaMK-IV (Fig. 7) known to inhibit apoptosis by
phosphorylation of CREB as described above (reviewed in Ref. [393])
and the prosurvival kinase Akt, suggesting that both CaMK-IV and
Akt may be important players in the induction of ischemic tolerance
mediated by the upstream CaMKK activity.
Studies indicate that CaMK-II may also have a proapoptotic function.
Inhibiting CaMK-II using the inhibitor KN-62may protect fromneuronal
cell death induced by NMDA or hypoxia in fetal rat cortical cultures
[394]. This is explained by insults leading to NMDA-mediated neuronal
death initiated by imbalanced Ca2+ and Na+ inﬂux into cells, which
could activate a number of downstream systems including CaMK-II-
mediated phosphorylation. Pretreatment with the CaMK-II inhibitor
KN-62 reduced Ca2+ transients induced by NMDA and shortened the
time when Ca2+ reached the basic level after stimulation. These results
indicated that CaMK-II is involved in phosphorylation of the NMDA
channel potentiating its activity. Indeed it has been shown that the
NMDA channel regulatory subunit contains a CaMK-II phosphorylation
site (reviewed in Ref. [224]). On the other hand, this may not be the
only way CaM-dependent kinases trigger neuronal cell death. Depolar-
ization of neuronal cells is another way that leads to brain cell death.
Takano et al. [395] found that inhibiting CaM and CaMK-II by a variety
of inhibitors preventeddeath of cortical neurons induced by the alkaloid
veratridine, a voltage-sensitive Na+ channel activator. A possible expla-
nation for this observation is that increased Ca2+ in the cell leads
to CaMK-II activation followed by phosphorylation and activation of
L-type Ca2+ channels. This is supported by the observation described
in the same article that the L-type Ca2+ channel blocker nifedipine con-
tributed to cell viability. Based on these results the authors suggest CaM
and CaMK-II as targets for anti-stroke therapies. Supporting the view of
a pro-apoptotic function of CaM and CaMK-II it has been shown that the
CaM inhibitor DY-9760e protects against neuronal death [396]. In con-
trast to in vitro studies, work by Hashiguchi et al. [397] indicates that
DY-9760e when applied post-ischemically mainly inhibits Ca2+/CaM-
dependent neuronal nitric oxide synthase (nNOS) and not CaMK-II
and CaN in the model of CaM antagonist-mediated delayed neuronal
death in gerbil hippocampus. This indicated that inhibition of nitric
oxide formation by nNOS, known to cause nitrotyrosine-mediated pro-
tein dysfunction, might correlate with the neuroprotective effect of the
CaM antagonist.
Shirasaki et al. [398] showed that expressing CaM with inactivated
Ca2+-binding sites renders cortical rat neurons resistant to a variety of
neuronal death-inducing insults, including depolarization by KCl. Over-
expression of PEP-19, a brain protein thought to sequester CaM in a
Ca2+-independent manner, similar to neurogranin as mentioned
above, prevents glutamate-induced cell death, and PEP-19wasmarked-
ly reduced after glutamate treatment resulting from calpain-mediated
degradation [399]. These investigations suggest that CaM activation
may naturally be controlled by PEP-19 and when PEP-19 is degraded
CaMmay activate target proteins involved in proapoptotic functions.
A proapoptotic function of CaMK-II was also found in the embryonic
stem cell line P19 stably transfected with the microtubuli modulating
protein τ (tau), a cell model system to study processes relevant for
Alzheimer's disease (AD). Neuroﬁbrillar tangles composed of the hyper-
phosphorylated τ protein are AD hallmarks. Apoptotic cell death during
neuronal differentiation of these cells induced by retinoic acid was evi-
dent in contrast to cells not expressing the τ protein [400]. As CaM and
CaMK-II inhibitors protected tau/P19 cells and as CaMK-II phosphorylates
τprotein at tubulin interaction sites the authors suggest that the τprotein
may dissociate from microtubules and may translocate into the nucleus
where it activates apoptosis-mimicking neurodegenerative processes in
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was found in lymphoblasts of AD patients [401]. These cells escape from
undergoing serumdeprivation-induced apoptosis as compared to control
cells. ERK1/2 seems to be involved in this process, as ERK1/2 activity
is lower in these cells and ERK1/2 inhibition in normal cells prevents
apoptosis. CaM seems to be involved in ERK1/2 downregulation
and preventing cell death of AD lymphoblasts as CaM inhibitors lead
to increased ERK1/2 activity and accelerated apoptosis due to serum
deprivation.
Lewy bodies, a hallmark of Parkinson's disease (PD) contain large
amounts of α-synuclein, which may negatively regulate the protein
phosphatase A2 (PPA2), known to have a neuroprotective function.
Yang et al. [251] overexpressed α-synuclein in neuronal cells and found
that PPA2 was phosphorylated at a known Src phosphorylation site
(Y307) decreasing its activity and levels of phospho-activated Src were
enhanced compared to control cells. Importantly, CaM/Src complex for-
mation was also higher after α-synuclein expression. The CaM-
dependent activation of Src was earlier demonstrated by Fedida-Metula
et al. [402]. The cytotoxic effect of α-synuclein could be ameliorated
through activating PPA2 by ceramide C2 or by buffering Ca2+. Theseﬁnd-
ings lead to the hypothesis that neurodegeneration in PD induced by α-
syuclein is mediated by Src/CaM-dependent inactivation of PPA2.
Retinopathy involving death of retinal ganglion cells (RGCs) leading
to dysfunction of the vision is a major complication in diabetes. CaMK-II
is known to be involved in RGC death. Diabetic mice exhibit massively
induced CaMK-II and active phosphorylated CaMK-II levels in RGCs. In-
hibition of CaMK-II activity by downregulation of the enzyme using
siRNA or speciﬁc inhibitors protected from diabetes induced RGC apo-
ptotic death [403]. In addition, the plant-derived natural polyphenol
resveratrol known to have neuroprotective properties could be shown
to prevent diabetic retinopathy induced by CaMK-II activation indicat-
ing its potential therapeutic value. As suggested by the authors, one
way CaMK-II could be transcriptionally regulated is by the action of
voltage-gated Ca2+ channels known to regulate Ca2+-dependent gene
expression and to contribute to RGCs apoptotic death (reviewed in
Ref. [403]). These results were later supported and extended by a
study of Li et al. [404] using the macaque choroid-retinal endothelial
cell line RF/6A. They found that hyperglycemia-induced apoptotic cell
death ismediated by extracellular ATP-triggered Ca2+ entry and depen-
dent on CaMK-II activity. Both the Fas-dependent and mitochondria-
dependent apoptotic pathways were affected by inhibitors blocking
Ca2+ entry and CaMK-II function in these cells.
Amajor reason for blindness is ischemic injury of the retina. CaN activ-
ity is increased during transiently induced ischemia leading to cell death
[405]. CaN directly interact with and dephosphorylates the prosurvival
kinase Akt. In addition, as mentioned above, the proapoptotic protein
Bad is dephosphorylated by CaN, constitutively activated by cleavage,
and translocates to the mitochondria where it interacts with the
antiapoptotic proteins B-cell lymphoma2protein (Bcl-2) and Bcl-XL lead-
ing to mitochondria failure followed by release of proapoptotic proteins
and activationof caspases,whichﬁnally leads to cell death. TheCaN inhib-
itor FK506 (tracolimus) reduces Akt and Bad dephosphorylation so
protecting from ischemia-induced retinal cell death. Huang et al. [406]
showed that intraocular pressure leads to cleavage and activation of
CaN in experimental glaucoma followed by induction of a retinal ganglion
cell death pathway involving the same players as in the above described
ischemia model, a process which can be blocked by CaN inhibitors. The
same group showed later [407] that activation of CaN in normal retinal
ganglia by adenovirus-mediated gene transfer caused neuronal degener-
ation. Based on these combined results on chronic and acute retinal
ganglion cells degeneration by a speciﬁc CaN-dependent pathway new
possibilities for therapeutic interventions have been proposed [407].
Preserving astrocyte viability during spinal cord injury is considered
a main issue for successful recovery. Hypoxic/ischemic stress in spinal
astrocytes targets primarily the ER and mitochondria. As mentioned
above, CaMK-II induces apoptosis through the JNK pathway [378] andCaMK-IIγ is involved in linking the ER and mitochondrial apoptotic
pathways [381]. Liu et al. [408] using an in vitro oxygen/glucose depriv-
ing model found that hypoxia/reoxygeneration conditions lead to ROS
accumulation and CaMK-II activation needed for the direct phosphory-
lation and activation of apoptosis signal-regulating kinase 1 (ASK1).
This kinase then induces JNK-mediated death of spinal astrocytes.
Downregulation of CaMK-IIγ reduced ASK1, JNK and 38 kDa mitogen-
activated protein kinase (p38MAPK) activation and apoptotic cell
death indicating that CaMK-IIγ plays an important role in the death of
spinal cord astrocytes after injury. In support of these ﬁndings Lu et al.
[409] recently found that CaMK-II is stimulated in rat hippocampal
slices exposed to oxygen glucose deprivationmimickinghypoxia–ische-
mia. Several events including increased activity of p38MAPK leading to
hypoxia induced neuronal cell death could be blocked by addition of the
CaMK-II inhibitor KN-93 strongly indicating an involvement of this en-
zyme in hypoxia-induced neuronal cell death.
CaM could be involved in neuronal apoptosis by its direct interaction
with FK506-binding protein 38 (FKBP38), an enzyme that suppresses
the antiapoptotic protein Bcl-2 through its prolyl cis/trans-isomerase ac-
tivity. Ca2+/CaM activation is required for the interaction of FKBP38
with Bcl-2 and its regulatory function [410]. Interestingly, CaM/FKBP38
interaction occurs in a novel dual intramolecular way where the C-
terminal lobe of CaM interacts with the C-terminus of FKBP38 enabling
the N-terminal lobe of CaM to interact Ca2+-independently with the
catalytical domain of FKBP38. This interaction leads to the activation of
this enzyme and thereby suppresses the antiapoptotic function of Bcl-2
[411]. Active site-directed inhibition of FKBP38 has been shown to in-
crease the survival of neuroblastoma cells challenged with apoptotic
stimuli and to provide neuroprotection and neuroregenerative effects in
a rat ischemia model [412].
4.3. Calmodulin function in cardiomyocytes death
CaMK-II has been demonstrated to have proapoptotic function in
cardiomyocytes. Zhu et al. [413] showed that inhibition of CaMK-II pro-
tects from β1-adrenergic receptor stimulation-induced apoptosis in cul-
tured ventricular myocytes and overexpression of the cardiac CaMK-IIδC
enhanced the effect of β1-adrenergic stimulation. The proapoptotic activ-
ity of CaMK-II was also demonstrated in vivo using mice genetically
engineered to express a speciﬁc CaMK-II inhibitory peptide [414]. Persis-
tent β-adrenergic stimulation in the failing heart leads to cardiomyocyte
apoptosis mediated by PKA-dependent activation of CaMK-II. Using a
transgenic mouse model and cultured feline ventricular myoctes with
expression of a PKA speciﬁc inhibitor Zhang et al. [415] showed that
β-adrenergic signaling leads to PKA-dependent cardiomyocyte death
and PKA-independent cardioprotection. PKA inhibition prevented cyto-
solic and sarcoplasmic reticulum Ca2+ overload, and CaMK-II activation
exerted a cardioprotective function mediated through a cAMP/Rap1/
Rac/ERK-dependent pathway. These results indicated that inhibition of
PKA could be an effective treatment of heart failure induced by β-
adrenergic stimulation of CaMK-II.
Cardiac hypertrophy is characterized by a loss of myocytes due to
apoptosis. Circulating angiotensin II (Ang-II), which levels are increased
in heart failure, may contribute to the death of myocytes. Ang-II induces
apoptosis through increased CaMK-II activity mediated by ROS and
followed by p38MAPK activation ﬁnally leading to cell death involving
the intrinsic apoptotic pathway [416]. Interestingly, Ang-II or ROS can
activate CaMK-II at very low Ca2+ concentrations and in the presence
of the CaM inhibitor W-7 in vitro resetting the Ca2+/CaM-dependence
of CaMK-II. CaMK-II plays as well a proapoptotic role in irreversible is-
chemia–reperfusion (I/R) injury in the heart as the CaMK-II inhibitor
KN-93 and a CaMK-II inhibitory peptide enhanced the contractile recov-
ery in parallel with a decreased extent of infarction and the decreased
presence of apoptotic markers [417].
Cell death by I/R is induced by elevated mitochondrial Ca2+ uptake
through the mitochondrial permeability transition pore (mPTP) and
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to both apoptotic and necrotic cell death. Necrotic cell death then
leads to a severe inﬂammatory response damaging the tissue. It is
well known that the latter response is mediated through NFκB,
which is released from its inhibitor IκBα, that undergoes phosphor-
ylation followed by proteosomal degradation, and NFκB translocates
to the nucleus where it positively regulates the transcription of a
number of proinﬂammatory cytokines and other factors. A study by
Ling et al. [418] indicated that CaMK-IIδ is involved in inﬂammation,
infarct and ventricular malfunction induced by myocardial I/R and
by NFκB. CaMK-IIδ knock-out mice were protected from I/R damage
and inhibited I/R-induced inﬂammation and NFκB-mediated gene
upregulation. These combined results are not in line with studies
showing that CaMK-II may be beneﬁcial in reversible I/R injury
where phosphorylation of phospholamban at Thr17 by CaMK-II
seems to be important in the stunned heart [419].
As described above CaMK-II is involved inmediating ER stress to the
mitochondria-dependent apoptotic signaling pathway. Roe and Ren
[420] found that oxidative activation of CaMK-II plays a major role in
ER stress-induced apoptosis of cardiomyocytes. The effect of
tunicamycin, an ER stress inducer, which leads to cardiomyocyte abnor-
malities and apoptosis could be inhibited by the CaMK-II inhibitor KN-
93 in a similar way as achieved with cardiac speciﬁc overexpression of
the antioxidant catalase. Recent literature shows that the effect of
CaMK-II on mPTP is mediated through increasing the mitochondrial
Ca2+ uniporter (mCU) current and reducing its Ca2+ tolerance. A
cardiac and mitochrondria targeted CaMK-II inhibitor prevented
mPTP opening, mitochondrial disruption and protected from I/R
injury-mediated apoptotic cell death in vivo similar to known
mPTP inhibitors such as cyclosporine A [421]. The same study indi-
cates that CaMK-II may directly regulate the function of the mCU
by phorphorylating it at serines 57 and 92.
Another CaM-dependent apoptotic pathway was described by Li
et al. [422]. HEK293 cells transformed with the T-large antigen showed
increased expression of the potassium channel Kv4.3 transcriptionally
induced by the activity of the Sp1 transcription factor, which itself is
controlled by the large T-antigen. The Kv4.3 K+ channels are associated
with a variety of diseases including heart failure and diabetes. One ex-
ample is hypertrophic heart where Kv4.3 channel expression is gradual-
ly decreased. Inactivation of Kv4.3 leads to CaMK-II-mediated apoptosis
and necrosis that can be reversed by the CaMK-II inhibitor KN-93 [422].
The authors suggest that downregulation of this channelmay lead to the
dissociation of CaMK-II from the channel followed by enzymatic activa-
tion of CaMK-II and initiation of a cell death inducing process in hyper-
trophic hearts.
Protein dephosphorylation by CaN may counteract the activity of
proapoptotic kinases in the heart. Guo et al. [423] found that pretreatment
of rat cardiomyocytes with the regulatory subunit of CaN (CNB) activates
CaN,which reduces cell death in response to hypoxia/reoxygenation inju-
ry that resembles the I/R injury model. This conﬁrmed earlier observa-
tions (reviewed in Ref. [423]), indicating an important beneﬁcial role of
CaN in hearts physiology. Guo et al. also found [423] that pretreatment
of cardiomyocytes with CNB, prior to injury causing insults enhanced ex-
pression of Bcl-2 and Bcl-XL indicating a function of these antiapoptotic
proteins in the protective role of CaN in the heart [423]. However, it is
not known at the present time, which are the critical direct targets of
CaN for its antiapoptotic function in the heart. Not surprisingly, also
proapoptotic functions of CaN in the heart induced by the β-adrenergic
pathway have been described earlier [424] making it difﬁcult to judge
whether increasing CaN activity in the heart would be of general beneﬁt
for protecting patients from heart failure.
A role of microRNA in the regulation of cardiac Ca2+-mediated apo-
ptosis was recently found by Cha and collaborators [425]. They showed
that micro-RNA-145 repressed the expression of CaMK-IIδ, reduced
ROS-induced Ca2+ overload and suppressed apoptosis by directly
targeting CaMK-IIδ.4.4. Calmodulin functions in the death of platelets, hepatocytes and
pancreatic cells
The non-nucleated platelet cells have important functions in the in-
tegrity of endothelium and homeostasis. CaM is attached to various cell
surface receptors in platelets, and CaM inhibitors affect the receptor-
mediated function of platelets. Wang et al. [426] found that the CaM in-
hibitors W-7, tamoxifen and triﬂuoperazine (TFP) all induced platelet
apoptosis through the mitochondrial pathway. CaM antagonists did
not impair platelet activation but affected adhesion and aggregation.
As CaM antagonists increase intracellular Ca2+ levels it is suggested
that mitochondrial inner membrane potential loss may be caused by
mitochondrial Ca2+ overload. Thus, patients treated with CaM antago-
nists may suffer from thrombocytopenia due to the proapoptotic effect
of these drugs on platelets.
It is well known that cytotoxic effects increase intracellular Ca2+, a
process that may be mediated by CaM. As an example, Tsutsui et al.
[427] showed that D-galactosamine (GalN), a hepatotoxic compound
that induces apoptosis, involves Ca2+ and CaM activity. Interestingly,
increase of GalN-induced apoptosis seems to be associated with an ini-
tial increase in a perinuclear Ca2+ signal followed by its diffusion into
the cytoplasm, whereas the necrotic effect of GalN is Ca2+ independent
indicating that GalN operates through different mechanisms leading to
cell death.
An early study by Yu et al. [428] indicated that CaM overexpression
in pancreatic β-cells might lead to a rise in blood glucose, which is pre-
ceded by apoptotic β-cell death. As inhibition of nNOS prevented the
CaM-induced hyperglycemia and β-cell death the authors speculated
that CaM overexpression might sensitize β-cells to Ca2+-dependent
nNOS activation triggering cell death.
4.5. Calmodulin functions in the immune system and HIV-induced cell
death
Earlywork indicated an active role of Ca2+ and CaM in glucocorticoid-
induced apoptosis in immature T-cells. Buffering sustained elevation of
Ca2+ concentration induced by glucocorticoid with Quin-2 or treatment
of cells with the CaM inhibitor calmidazolium prevented DNA fragmenta-
tion and apoptotic death [429]. Furthermore, Dowd et al. [430] found an
up to 10-fold increase of CaM mRNA level in WEHI7.2 lymphocytes
after glucocorticoid treatment indicating steroid hormone-regulated
expression of CaM. Elevated CaM expression may be important for the
execution of the apoptotic program supported by the observation that
treatment with the CaM inhibitor calmidazolium protected lymphocytes
from apoptosis.
Amajor effect of HIV infection is the apoptotic death of T cells known
to be frequentlymediated by Ca2+ signaling. Itwas found that CaMmay
be involved in HIV-triggered and Fas-dependent T-cell apoptosis [431]
as transfection of cells with vectors expressing the wild type gp160
HIV envelope protein, in contrast to a truncated version lacking the
CaM binding domain, enhanced apoptosis. Moreover, the CaM antago-
nists TFP and tamoxifen inhibited enhancement of Fas-triggered
apoptosis by gp160. It has also been found that an increase in CaM
concentration is needed for gp160-dependent enhanced Fas-mediated
apoptosis, where caspase-3 activity is involved in the apoptotic process
in Jurkat T cells with inducible pg160 expression [432]. This process,
which requires CaM binding to gp160, can be blocked by a single
point mutation in the CaM-binding site of gp160 [433]. No effect of
this mutation and several other point mutations in the CaM binding
sequence of gp160, which all abolished the apoptotic effect of gp160,
was found on viral replication and envelope expression supporting the
speciﬁc effect of CaM on apoptosis [433]. In addition, CD4+ T-cells
from acquired immunodeﬁciency syndrome (AIDS) patients showed
enhanced spontaneous T-cell apoptosis compared to healthy controls.
In the presence of the CaM inhibitors mentioned above the rate of apo-
ptosis was signiﬁcantly inhibited in vitro [434]. Conﬁrming these data it
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gp120, in human CD4+ cells induced apoptosis mediated by Ca2+/
CaM-dependent intracellular Ca2+ release [435]. The use of the CaM
antagonist W-7 and the cell permeable Ca2+ chelator BAPTA-AM in
the gp160 expressing UE160 cells could prevent nuclear fragmentation,
a typical apoptotic hallmark. The same group also showed later that the
C-terminus of gp160 is responsible for direct complex formation with
CaM and that this complex is essential for the initiation of cell death of
the monocytoid cell line U937 that expresses high levels of CD4 [436].
Contini et al. [437] found that HLA class I-mediated apoptosis of
Epstein–Barr virus speciﬁc CD8 cytotoxic T cells through Fas ligand
(FasL)/Faswas dependent among other factors on the CaMK-II signaling
pathway. This is followed by nuclear translocation of the transcription
factor together with NFκB,was responsible for inducing FasL expression
followed by T-cell apoptosis. In addition, apoptosis induced upon activa-
tion of the B-cell receptor (BCR) in B-lymphocytes appears to involve
the participation of CaM. Thiswas shown bydecreasing the levels of cel-
lular CaM to 40% of its original value by knocking down the CaMII gene
in DT40 cells, which partially protected from BCR-induced apoptosis
[147].
4.6. Calmodulin-mediated mechanisms of apoptosis in tumor cells
CaM antagonists have been shown to contribute to the induction of
apoptosis in cancer cells. An early study by Frankfurt et al. [438] demon-
strated that blocking CaM function using the CaM antagonists TFP and
W-7 in combinationwith the estrogen receptor (ER) antagonist tamox-
ifen induced apoptosis in breast cancer cell lines and also in cells freshly
isolated from ER-positive and ER-negative breast cancer cells in a syner-
gistic manner. The apoptotic effect of tamoxifenwas attributed to its in-
hibitory effect on CaM function independent of its effect on the ER [439],
as it has been shown earlier that this agent binds to and inhibits CaM
[440].
Lack of Fas expression in the aggressive human cholangiocarcinoma
may explain the resistance of this cancer type to generally used cancer
treatments. A study by Pan et al. [441] showed that TFP and tamoxifen
act in a Fas-dependent fashion to induce apoptosis in cholangiocarcino-
ma cells. Fas/APO1 (CD95) is a major cell death receptor belonging to
the TNF-α superfamily. TFP and tamoxifen induced apoptosis only in
cholangiocarcinoma cells that expressed Fas, indicating its involvement
in the apoptotic cell deathmechanism. Cells with functional Fas expres-
sionwere not tumorigenic in nudemice in contrast to cells that lost Fas,
underlining the importance of the Fas signaling system to prevent
uncontrolled cell proliferation. Furthermore, McDonalds' group also ob-
served that interferon-γ increased the susceptibility towards the CaM
antagonists to induce caspase-dependent and caspase-independent
apoptosis in cholangiocarcinoma cells weakly expressing Fas [442]. In
addition, they found that CaN and CaMK-II are not likely to be involved
in the CaM-mediated cell death mechanism, as inhibitors of these pro-
teins were not effective in inhibiting apoptosis. A possible mechanism
of CaM-triggered Fas-dependent apoptosis was indicated by the discov-
ery of a direct interaction between CaM and the cytosolic death domain
(DD) of Fas in a 2:1 (mol/mol) CaM/Fas ratio with dissociation constant
of 2 μM and with both the N- and C-lobes [443–445]. Binding was
shown to be Ca2+-dependent and speciﬁc to Fas, as other death recep-
tors (DR) such as the TNF-α family receptors DR4 andDR5did not inter-
act with CaM. Amutation in the CaM-binding sequence of Fas decreased
CaM-binding as well as Fas-mediated apoptosis in Jurkat T-cells.
Upon Fas activation an initial increased interaction between Fas and
CaM was observed after 30 min followed by a decrease to 50% after
2 h compared to controls. Direct CaM/Fas interaction and induction of
Fas-mediated apoptosis by CaM antagonists were also detected in oste-
oclasts indicating a general signiﬁcance of these ﬁndings [446].
Interestingly, knockdownof the Fas adaptor protein FADD in pancre-
atic cancer cells led to resistance towards Fas-mediated signaling that
otherwise provokes cell death [447]. Instead, Fas initiated a survivalpathway in the absence of FADD that involved ERK activation and
could be inhibited by CaM antagonists. It was also found that FADD
knockdown leads to a recruitment of CaM, Src and phosphorylated Src
to the Fas-activated signaling complex. CaM directly interacted with
the SH2 domain of Src as describe above, leading to its phosphorylation
suggesting a crucial role of CaM in Fas-mediated FADD-independent cell
survival. This pathway seems to be also independent of a c-FLIP (an en-
zymatically inactive caspase-8 homologue)-mediated signaling mecha-
nism working through NFκB which is a known cell viability supporting
process also found to operate in cancer cells. Rapold and collaborators
[448] found that Fas induced a Ca2+/CaMK-II-dependent pathway
with involvement of ERK1/2 phosphorylation leading to lipolysis in
3T3-L adipocytes conﬁrming the existence of a Fas-driven non-
apoptotic pathway that involves CaM signaling.
TNF-related apoptosis-inducing ligand (TRAIL) signals through the
TNF-α receptor family members DR4 and DR5 to induce extrinsic
apoptosis in a variety of cancer cells but is not generally toxic to most
normal cells making it a promising anticancer candidate drug. On the
other hand, TRAIL is only effective in combination with other drugs in
TRAIL-resistant tumors. Hwang and collaborators [449] found that
co-treatment of lung tumor cells with TRAIL and the CaM antagonist
ﬂuphenazine-N2-chloroethan or the use of CaM siRNA sensitized the
cells to TRAIL-induced apoptosis. The authors proposed that this CaM
antagonist might inhibit the TRAIL-induced interaction of the apoptosis
inhibitory protein c-FLIP, earlier shown to directly bind to CaM [450]. In
addition, Chen et al. [451] showed that the Fas-mediated DISC contains
CaM and that Fas enhanced the recruitment of CaM to the DISC in chol-
angiocarcinoma cells. A second possibility of CaM antagonist function in
the TRAIL-mediated pathway is through inhibiting the prosurvival
Akt-dependent pathway. Indeed, the CaM antagonist inhibited Akt
phosphorylation leading to decreased expression of death inhibiting
molecules such as c-FLIP and inhibitor of apoptosis (IAP) family mem-
bers [449]. Fujikawa et al. [452] showed that CaMK-II through Akt, likely
involving direct phosphorylation, might regulate TRAIL-induced
caspase-8-dependent apoptosis in ﬁbroblast-like synovial cells as inhib-
itors to both kinases augmented apoptosis. A recent study byKaminskyy
et al. [453] supports an antiapoptotic activity of CaM in TRAIL signaling
based on the observation that Ca2+/CaM suppressed the survival of
non-small cells lung carcinoma (NSCLC) cells with TRAIL-mediated
upregulation of the short c-FLIP form. The latter protein is induced
in cells, which are resistant to undergo TRAIL, DR4 and caspase
8-mediated apoptosis, which normally occurs in most NSCLC cells.
In prostatic cancer cells a CaM/CaN-dependent signaling pathway
leading to apoptotic cell death and induced by the SERCA inhibitor
thapsigargin was discovered by Tombal et al. [454]. In contrast to the
most frequently used anti-cancer drugs, which are only effective in rap-
idly proliferating cells, thapsigargin induces cell death in malignant
androgen-independent prostate cancer cells proliferating at a low rate.
Typical consequences of the activated CaM/CaN signaling pathway
leading to cell death such as translocation of NFAT to the nucleus and
Bad to the mitochondria after dephosphorylation of both proteins as
well as release of cytochrome c from the mitochondria to the cytosol
was observed.
Inhibition of CaMK activity has been demonstrated to induce apo-
ptosis in human promyelocytic leukemia cells. The CaMK inhibitor
KN-62 and the CaM antagonist TFP at nontoxic concentrations were
shown to sensitize cells to etoposide (VP-16) cytotoxicity [455]. This
effect was attributed to enhancement of the topoisomerase II (TOPO-
II)-induced DNA cleavage complex formation followed by S phase-
speciﬁc apoptosis of the cells. The used inhibitors enhanced phosphory-
lation of TOPO-II, whichmay explain their sensitizing effect on the cells
resistant to VP-16 to undergo TOPO-II-mediated DNA cleavage. Newer
results from the same group using VP-16 sensitive and insensitive
HL-60 cells indicated that the CaN inhibitor KN-62modulates the effect
of VP-16 only in the S phase of the cell cycle in VP-16 sensitive cells
whereas in VP-16 resistant cells nontoxic concentrations of KN-62 had
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sible explanation of these results is that KN-62 both stabilizes TOPO-
II α and β form-induced DNA cleavage as well as protein levels and
phosphorylation of the β, form which is not cell cycle regulated in
contrast to the α form. In a more recent article, the effect of the
CaMK selective inhibitor KN-93 on choriocarcinoma cells was tested
[231]. Among other effects KN-93 induced apoptosis in these cells as
demonstrated by exposure of phosphatidylserine monitored by
annexin-V staining, DNA fragmentation and loss of the mitochondri-
al membrane potential.
The clinically widely used drug 5-ﬂuorouracil (Adrucil™) (5-FU) for
treatment of a variety of cancers is known to lead to genome impair-
ment and inducing apoptosis through mechanisms involving p53.
Recently, Can et al. [457] discovered that that 5-FU treatment lead to in-
ﬂux of Ca2+ from the extracellular space and that CaM-dependent
phosphorylation of p53 at three positions (Ser15/33/37) was necessary
for its function to activate an apoptotic pathway in colon carcinoma
cells. However, it is not known whether this is a direct phosphorylation
by CaMK(s) or indirect by other upstream kinase(s). Following p53 ac-
tivation caspase-8 was activated through the DR5/DISC pathway ﬁnally
leading to activation of downstream executer caspases and apoptotic
cell death.Fig. 11. Calmodulin action on systems controlling autophagy. The scheme depicts the major co
tems controlling this process. ADPR, ADP-ribose; AMPK, AMP-activated protein kinase; Bcl-2, B-
dependent protein kinases I/III/IV; CaMKKβ, CaM-dependent protein kinase kinase β; CaN, ca
eEF2, eukaryotic elongation factor 2; eEF2K, eEF2 kinase (CaMK-III); ER, endoplasmic reticulum
LRRK2, leucin-rich repeat kinase 2; mTOR, mammalian target of rapamycin; mTORC1, mTOR co
tential melastatin 2; TSC1/2, tuberous sclerosis proteins 1 and 2; VPS34 (PI3K-III), phosphatidy5. Calmodulin in regulation of autophagy
5.1. General comments on the functional roles of autophagy
Autophagy is a physiological mechanism by which cells remove in a
controlled fashion long-lived cellular proteins or protein aggregates,
defective intracellular organelles and/or pathogens, by engulﬁng these
components into intracellular multimembrane vesicles denoted
autophagosomes and delivering them for their disposal to lysosomes
(reviewed in Ref. [458]) (Fig. 11). Autophagy plays an important pro-
survival role especially under starving conditions accompanying many
physiological functions but also plays a pro-death role under certain
conditions. Autophagy participates in the immune response, including
the clearance of bacteria and viruses (reviewed in Refs. [459–463]);
metabolic homeostasis (reviewed in Ref. [464]); organismal develop-
ment (reviewed in Refs. [465,466]); and normal physiological aging
(reviewed in Ref. [467]). Autophagy also participates in the pathogene-
sis of various diseases including cancer (reviewed in Refs. [468–471]).
The carcinogenic transformation of cells is frequently associated with
the suppression of autophagy, suggesting that its induction with some
drugs could open venues for new anti-cancer therapeutic strategies
(reviewed in Ref. [472]).mponents participating in autophagy and the different calmodulin (CaM)-dependent sys-
cell lymphoma 2 protein; Bcl-XL, B-cell lymphoma-extra large protein; CaMK-I/III/IV, CaM-
lcineurin; DAPK, death-associated protein kinase; DRP-1, DAPK-related protein kinase 1;
; FKBP38, FK506-binding protein 38; IP3, inositol-1,4,5-trisphosphate; IP3R, IP3, receptor;
mplex C1; Rheb, Ras homolog-enriched in brain G protein; TRPM2, transient receptor po-
linositol 3-kinase type III.
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whole organelles, cytoplasmic components and/or pathogens are
degraded in vesicular structures denoted autophagosomes after fusion
with lysosomes (reviewed in Refs. [473,474]) (Fig. 11). Another type
is microautophagy, in which cytoplasmic cargo, including piecemeal
organelle fragments, are directly engulfed into lysosomes/vacuoles by
the formation of an autophagic tube fromwhich the vesicles are escised
(reviewed in Ref. [475]). A third type is chaperone-mediated autopha-
gy, in which proteins bound for degradations form complex with chap-
erones that facilitate their direct delivery to the lysosomal lumen
(reviewed in Ref. [476]). Although autophagy and apoptosis are mech-
anistically different cellular processes, there are some common regula-
tory proteins that intervene in both of them, such as the anti-apoptotic/
anti-autophagy regulators Bcl-2 and Bcl-XL, and the all-important ser-
ine/threonine kinase DAPK among others, thus these systems establish
a vivid crosstalk controlling the fate of the cells by undertaking one
of these pathways to either achieve cell restoration or cell death
(reviewed in Refs. [373,477]). The enzymes PARP1/2 appears to play
a pivotal decision making role in directing the cells to authophagy or
apoptosis by Ca2+-mediated mechanisms after receiving an environ-
mental insult such as oxidative stress [32]. Also, the transient perme-
abilization of the mitochondrial membrane occurring during intrinsic
apoptosis triggers autophagy of the damaged mitochondrium
(reviewed in Ref. [478]), further linking both phenomena. In addition,
the dual-role played by DAPK as a decision maker in pro-survival or
pro-death signaling appears to be determined by the activation level
of the implicatedmechanisms, an ancient phenomenon that is phyloge-
netically conserved even in the worm C. elegans (reviewed in Ref.
[479]).
5.2. The calcium signal and the implication of calmodulin in autophagy
An important signaling component in autophagy is the mobilization
of calcium (reviewed in Ref. [85]), leading to the formation of the Ca2+/
CaM complex and the activation of an array of CaM-dependent target
systems that play prominent roles during this process (Fig. 11). Ca2+
mobilization during autophagy has been demonstrated to occur via IP3
receptors/Ca2+-release channels that might have a dual role: either
a suppressing-function of autophagy, when Ca2+ uptake by the mito-
chondria enhances oxidative phosphorylation and ATP levels decreas-
ing the activity of AMPK; or an enhancing function by different
signaling routes where CaM is implicated by activating CaMKKβ and
CaMK-I among other pathways (reviewed in Refs. [480–483]), inducing
the phosphorylation of AMPK as demonstrated in various tissues, see for
example [484]. Calcium mobilization during ER-stress induced for
example by 2-deoxyglucose is also a potent signal to activate the
CaMKKβ/AMPK pathway [485]. An upstream kinase denoted leucin-
rich repeat kinase 2 (LRRK2) appears to activate the CaMKKβ/AMPK
pathway, an effect that can be mimicked by NAADP, a lysosomal
Ca2+-mobilizing agent [486] (Fig. 1). This demonstrates that the
autophagy-initiating Ca2+ signal could have different origin. The Ca2+
signal activating the CaMKKβ/AMPK route leads to the phosphorylation
of the tuberous sclerosis proteins 1/2 (TSC1/TSC2) complex and the
downstream repression of mammalian target of rapamycin (mTOR)
with the subsequent induction of autophagy [482,487–489], a process
that is inhibited by Bcl-2 ectopically located in the endoplasmic reticu-
lum [488]. This mechanism was commented by Swerdlow and
Distelhorst [490] stressing the common implication of Bcl-2 both in ap-
optosis and autophagy. Although the intracellular mobilization of Ca2+
plays an important role in setting autophagy induced by mTOR inhibi-
tion [80], in S. cerevisiae a Ca2+-independent role of CaM has been ob-
served in the process of microautophagy, where cytosolic components
are directly delivered into the vesicular degradation systemby a special-
ized membrane invagination [491].
Interestingly, CaMKKβ can be by-passed in some circumstances, as
for example in TRAIL-induced autophagy where transforming growthfactor-β-activating kinase 1 (TAK1) acts as an activator of AMPK with-
out the involvement of the former [492]. And furthermore, AMPK can
also be bypassed in the Ca2+-mediated induction of autophagy as dem-
onstrated using embryonic ﬁbroblasts from AMPK-knockout mice
[493]. In addition, Guo and collaborators [494] described a CaMK-Iα/
AMPK-dependent but mTOR complex C1 (mTORC1)-independent au-
tophagic mechanism acting during acute neutrophilic inﬂammation of
the lung induced by lipopolysaccharides. Overall these observations
underline the existence of additional compensatory mechanisms unre-
lated to canonical autophagic pathways.
CaMK-III, also denoted as eEF2-kinase, plays an important role
controlling autophagy as its downregulation inhibits autophagy
and conversely its overexpression enhances this process [495,496].
This also suggests the existence of a CaM-mediated control of protein
synthesis during the autophagic process. Besides, a protective effect of
CaMK-III (eEF2-kinase)-mediated autophagy in cancer cells subjected
to metabolic stress has been described [497], and inhibition of CaMK-
III suppressed autophagy but promotes apoptosis when tumor cells
were subjected to pharmacological inhibition of Akt [498].
In accordance with the implication of mTOR inhibition in setting
autophagy, it is well known that the PI3K/Akt/mTOR pathway is in-
volved in cell survival, and as previously mentioned, activation of this
axis leads to inhibition of autophagy. As both PI3K and Akt activities
are regulated by CaM [499–501], this could represent another route by
which CaM exerts a repressive action on autophagy. This issue appears
to be quite complex, as suppression of autophagy by activating the
PI3K/Akt/mTOR pathway also appears to promote necrotic cell death,
at least in cell models where autophagy plays a pro-survival function
[502].
CaM-dependent serine/threonine kinases such as DAPK and other
members of this kinase family play important roles in autophagy by facil-
itating the formation of autophagosomes and stimulating vesicular traf-
ﬁc (reviewed in Refs. [373,374]). Thus, it was shown that both DAPK and
its related kinase DRP-1 participate in membrane bebbling and the for-
mation of autophagic vesicles [503]. Onemechanism is by the interaction
of DAPK with the microtubular-associated protein 1B (MAP1B) and the
autophagosomal protein Atg8 [504,505]. Moreover, DAPK also interacts
with and phosphorylates TSC2, thus suppressing the activity of the
TSC1/TSC2 complex. This results in the activation of mTORC1 promoting
cell survival and repressing autophagy under normal but not hyperactive
growth factor-stimulated MAPK signaling conditions [506]. CaM-
mediated activation of DAPK also induces the phosphorylation of
beclin-1 and its dissociation from their inhibitory regulators Bcl-XL and
Bcl-2, followed by the induction of the autophagic process [507,508]. In
a recent study, Han et al. [509] have shown that beclin-1 also interacts
with the ErbB2 receptor increasing its phosphorylation and activating
the Akt pathway. Furthermore, in breast carcinoma cells, which are resis-
tant to the ErbB2 tyrosine kinase inhibitor lapatinib, this agent disrupts
the ErbB2/beclin-1 complex increasing beclin-1 cytosolic concentration
and thereby facilitating the autophagic response. The IFN-γ-regulated
transcription factors ATF6 (activating transcription factor 6) and C/EBP-
β are essential for the expression of DAPK1 and the subsequent induction
of autophagy [510], while the degradation of DAPK, counterbalancing
IFN-γ action, is controlled either by its degradation in the proteasome
after polyubiquitination [511], or by lysosomal degradation after interac-
tion with TSC2 via its death domain [512].
The lack of supply of essential amino acids is a strong signal to induce
autophagy via the CaMKKβ/AMPK pathway resulting in the activation of
the autophagy-initiating UNC-51-like kinase (ULK1) and inhibition of
the negative regulator of autophagy mTORC1 [513]. The formation of
autophagosomes upon mTOR inhibition is concomitant with the synthe-
sis of phosphatidylinositol 3-phosphate (PI3P), and this phosphoinoside
interacts with the so-called WD-repeat protein interacting with phos-
phoinositides (WIPI) proteins located in the autophagosomal mem-
branes. In this context, it has been demonstrated that a CaMKK/CaMK-I
pathway contributes to the stimulation of WIPI-1 during Ca2+-
Table 3
Effects of distinct CaM antagonists on tumor cells.
CaM antagonist Tumor/cell/tissue Origin Effect References
B859-35 Neuroendocrine lung tumors Hamster Inhibits tumor growth in vivo [579]
Lung carcinoid NCI-H727, adenocarcinoma
NCI-H322 and NCI-H358 cells
Human Inhibits cell proliferation (at 0.001 pM–100 nM) [580]
Berberinea Hepatocellular carcinoma Bel7402 cells Human Arrest the cell cycle at G1 W-7 and TFP pontentiate
its action. Inhibits CaMK-II and MEK1, and p27
degradation (CaM-unrelated effects observed)
[585]
Calmidazolium (R24571) Breast adenocarcinoma MCF-7, T47D,
ZR-75-1 cells
Human Inhibits cell proliferation at the early to mid G1
phase of the cell cycle. Induces apoptosis-like
cell death potentiated by antiestrogen drugs
[165,439,588]
Serous cystadenocarcinoma ovary cells Human Inhibits cell proliferation and prevents EGF
binding to its receptor
[583]
Pituitary tumor GH3 cells (ER-positive) Rat Induces apoptosis-like cell death potentiated
by antiestrogen drugs
[588]
ASV-transformed cells Rat Inhibits cell cycle at late G1 [163]
Ehrlich ascites tumor cells Mouse Inhibits protein synthesis [605]
Astrocytoma C6 cells Rat Inhibits cell proliferation [589]
Chlorpromazine Leukemia cells Human and mouse Inhibits cell growth and clonogenicit [593]
Astrocytoma C6 cells Rat Inhibits cell proliferation [589]
Compounds 1, 2 and 3b Breast adenocarcinoma T-47D, MCF-7B,
MCF-7T and MDA-MB-231 cells
Human Inhibits cell proliferation [578]
Compound 48/80c Promyelocytic leukemia HL-60 cells Human Inhibits cell proliferation [154]
Dequalinium Astrocytoma C6 cells Rat Inhibits cell proliferation [87]d
Fluphenazine mustard Astrocytoma C6 cells Rat Inhibits cell proliferation [87]d
FPCE Lung cancer H1299 cells Human Sensitizes cells to TRAIL-induced apoptosis [449]
HBC Colon cancer HCT15 cells Human Inhibits cell proliferation (upregulates p21Cip1/Waf1) [333]
HBCP Colon cancer HCT15 cells Human Inhibits cell proliferation (upregulates p21Cip1/Waf1) [332]
J-8 Breast adenocarcinoma T-47D, MCF-7B,
MCF-7T and MDA-MB-231 cells
Human Inhibits cell proliferation [578]
Melanoma A375-SM cells Human Reduces cell invasiveness [641]
KS-501 and KS-502e Leukemic L1210 lymphocytes Mouse Inhibits cell proliferation (less effective in MDR variants) [594]
Melittin Serous cystadenocarcinoma ovary cells Human Inhibits cell proliferation and prevents EGF binding
to its receptor
[583]
Leukemia cells Human and mouse Inhibits cell growth and clonogenicity [593]
Astrocytoma C6 cells Rat Inhibits cell proliferation [589]
Phenothiazinef
(thiodiphenylamine)
Colon adenocarcinoma WiDr cells Human Inhibits cell proliferation [581]
Phenothiazinesg Glioma C6 cells Rat Inhibit cell proliferation [591]
Prochlorperazine Melanoma B16 cells Mouse Inhibits cell proliferation (DNA synthesis) [133]
Promethazine Colon adenocarcinoma WiDr cells Human Inhibits cell proliferation [581]
Rhodamine-123 Astrocytoma C6 cells Rat Inhibits cell proliferation [87]d
Tamoxifen Melanoma A375-SM cells and uveal
melanoma cells
Human Reduces cell invasiveness (effect unrelated
to ER antagonism but related to CaM inhibition)
[641]
Triﬂuoperazine Breast adenocarcinoma MDA-MB-231
and MCF-7 cells
Human Inhibits cell proliferation and colony formation [439,642]
Fibrosarcoma HT1080 cells Human Enhances Egr-1 expression inhibiting cell growth [293]
Glioma C6 cells Rat Inhibits cell proliferation [589,591,597]
Promyelocytic leukemia HL-60 cells Human Inhibits cell proliferation [154,592]
Leukemia cells Human and mouse Inhibits cell growth and clonogenicity [593]
Ehrlich ascites tumor cells Mouse Inhibits protein synthesis [605]
W-5 Serous cystadenocarcinoma ovary cells Human Inhibits cell proliferation and prevents EGF
binding to its receptor
[583]
Breast adenocarcinoma MCF-7 cells Human Inhibits cell proliferation (very weakly) [439]
W-7 Skin tumors Mouse Inhibits tumor promotion by DMBA plus teleocidin [595]
Melanoma B16 cells Mouse Inhibits cell proliferation (DNA synthesis) and
down-regulates metastasis-associated genes
[133,164,548]
Serous cystadenocarcinoma ovary cells Human Inhibits cell proliferation and prevents EGF
binding to its receptor
[583]
Breast adenocarcinoma MDA-MB-231
and MCF-7 cells (ER-positive and ER-negative variants)
Human Inhibits cell proliferation and colony formation [439,578,642]
Lewis lung carcinoma Mouse Inhibits metastasis development [549]
Colon adenocarcinoma WiDr cells Human Inhibits cell proliferation [581]
Thyroid papillary adenocarcinoma NIM 1 cells Human Inhibits IL-1 -induced cell proliferation (DNA synthesis) [586]
Hepatocellular carcinoma VX2-L cells Rabbit Inhibits cell proliferation (DNA synthesis) [584]
ASV transformed cells Rat Inhibits cell cycle at late G1 [163]
Solid sarcoma 180 Mouse Inhibits tumor growth in vivo [587]
Chemically-induced glioma GA-1 cells Rat Inhibits tumor growth in vitro and in vivo [590]
Glioma C6 cells Rat Inhibits cell proliferation [597]
Ehrlich ascites tumor cells Mouse Inhibits protein synthesis [605]
Promyelocytic leukemia HL-60 cells Human Inhibits cell proliferation and phagocytosis [592]
W-13 Breast adenocarcinoma MCF-7, ZR-75-1B and
T47D (ER-positive); LY2 and RR (ER-positive/TamoxR);
and MDA-MB-231 and MDA-MB-435 (ER-negative) cells
Human Inhibits cell proliferation and colony formation [576,577,642]
Promyelocytic leukemia HL-60 cells Human Inhibits cell proliferation and phagocytosis [592]
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action, as it also occurs in AMPK-deﬁcient ﬁbroblasts [514]. In addition,
CaMK-IV plays a protective role during ischemia–reperfusion (I/R) injury
of the liver by activating the prosurvival autophagic pathway in hepato-
cytes, as demonstrated in CaMK-IV knockout mice, where I/R produces
more extensive organ damage compared to controls and a reduction of
this damage by rapamycin, an agent which allosterically inhibits mTOR
[515]. An interesting example of the implication of CaMKKβ during
autophagy induced by virus infection is the activation of the CaMKKβ/
AMPK signaling pathway by viroporin, a rotavirus pore-forming protein
that releases Ca2+ from the endoplasmic reticulum [516,517].
Phosphatases counterbalancing the different kinases implicated in au-
tophagy are also important regulators of the overall process, as early dem-
onstrated by the inhibitory action of okadaic acid and other phosphatase
inhibitors onautophagy inhepatocytes, and theprotective effect that CaM
antagonists and CaMK-II inhibitors have on okadaic acid action
[518–520]. The assayed inhibitors mostly targeted protein phosphatase
type 2A (PP2A), possibly by dephosphorylating an inhibitory autophos-
phorylation site in DAPK resulting in the activation of this kinase during
ER stress-induced autophagy [521]. Nevertheless CaM is also implicated
in the dephosphorylation process, as CaN may also play a protective role
in autophagy. This was shown by the occurrence of enhanced autophagy
in CaN-defective strains of the worm C. elegans [522]. Furthermore, the
ubiquitin/proteasome and autophagy–lysosome pathways both degrade
the CaN inhibitory protein denoted regulator of calcineurin 1 (RCAN1)
in two mammalian cell lines, possibly enhancing CaN/NFAT signaling
during chaperone-mediated autophagy [523].
6. Calmodulin and tumor progression
The CaM-dependent signaling mechanisms regulating either cell
proliferation, programmed cell death or autophagy described above,
are all of great importance for tumor cell biology. In the following sec-
tions the implication of CaM-dependent systems in major physiological
processes relevant in tumorigenesis and tumor progression will be
discussed.
6.1. Calmodulin and tumor growth
The level of CaM in many tumor cells appears to be higher as com-
pared to cells from normal tissues. This was demonstrated for example
in chicken ﬁbroblasts transformedwith the Rous sarcoma virus [524], in
kidney epithelial cells infectedwithASV [163], in different rat hepatoma
cell lines [525–528], in rat ﬁbroblasts transfected with various PKC
constructs and oncogenes [529], and in human primary lung cancer
cells [530]. A positive correlation between the rate of cell growth and
the degree of tumor malignancy with the level of cellular CaM has
been postulated [525,527,528,530,531]. Increased CaM levels, mainly
in the cytosol and a concomitant decrease of membrane-bound CaM,
has been noticed in hepatoma cells compared to normal liver cells
[525,527]. The increased CaM expression in tumor cell lines was
shown to correlate with high intracellular Ca2+ and increased activity
of the CaM-dependent cyclic nucleotide PDE [525–528].Notes to Table 3:
ASV, avian sarcoma virus; B859-35, (–) enantiomer of dihydropyrine 3-methyl-5-3-(4,4-d
dicarboxylate-hydrochloride (niguldipine); CaMK-II, CaM-dependent protein kinase II; EGF, e
FPCE, ﬂuphenazine-N-2-chloroethane; IL-1α, interleukin-1α; MDR, multidrug resistant; ME
apoptosis-inducing ligand.
a An isoquinoline alkaloid.
b Compounds 1–3 are variants of the W series of naphthalenesulfonamides such as W-7 and
c Condensation product of N-methyl-p-methoxyphenethylamine with formaldehyde.
d Review article.
e Compounds isolated from the fungus Sporothrix sp. KAC-1985.
f Basic compound from which a family of related neuroleptic antipsychotic drugs are derive
g Assay of several phenothiazines.The levels of CaM are higher during active growth of normal tissues,
as it occurs during the postnatal development of testis and spermato-
genesis [532]. Moreover, cytosolic but not membrane-bound CaM
increased in normal regenerating liver during partial hepatectomy
concomitant with increased DNA synthesis [526]. These observations
point to higher CaM requirements in fast growing cells. In a study by
Chirigan et al. [533] it was shown that tumor cells growing indepen-
dently of serum have lower nuclear CaM levels, and CaM antagonists
more efﬁciently inhibit their proliferation as compared to serum-
dependent clones. Therefore, it was concluded that nuclear but not cy-
tosolic CaM plays a role in autonomic cell proliferation.6.2. Calmodulin and tumor-associated angiogenesis
Tumor growth requires an efﬁcient supply of oxygen, nutrients and
systemic and/or locally-produced endocrine/regulatory factors, and the
removal of waste products. To attain sizes larger than 2 mm,were simple
diffusion starts to be inefﬁcient, tumors require a capable blood supply to
perform those tasks. This is bestowed by what is called tumor-associated
angiogenesis. This process involves the development of newblood vessels
by either the trans-differentiation of tumor stem cells into vascular cells
[534] and/or the sprouting and growth of already formed peripheral
vessels. Overall, this yields a competent neo-formed tumor-associated
vascular system that is highly regulated and that has been targeted for
anti-tumor therapeutic purpose (reviewed in Ref. [535]). Hypoxia is a
major driver of tumor-associated angiogenesis, as hypoxic stresses occur-
ring in poorly irrigated tumor microenvironments increases the cytosolic
concentration of Ca2+ and hence the formation of the Ca2+/CaM com-
plex. This leads to an enhancement of the transcriptional activity of
hypoxia-inducible factor 1 (HIF-1) increasing the expression of vascular
endothelial growth factor (VEGF) and hence angiogenesis, a process
that can be inhibited by CaM antagonists [536–539].
Nitric oxide (NO) has been shown to be an important regulator of an-
giogenesis, apparently acting in a biphasic fashion depending of the
amount produced by the CaM-dependent enzyme eNOS in endothelial
cells. NO has been demonstrated to control the upregulation of VEGF dur-
ing angiogenesis by increasing the transcriptional activity of HIF-1
(reviewed in Ref. [540]). Nevertheless, it has been demonstrated that ad-
dition of VEGF to endothelial cells induces the activation of the CaMKKβ/
AMPK pathway leading to angiogenesis without the concourse of NOS
[541]. Furthermore, embryonic angiogenesis mediated by activation of
the heterotrimeric Gα13 protein is due to the activation of the transcrip-
tion factor MEF2 (myocyte enhancer factor 2) with the participation of
CaMK-IV and histone deacetylase 5, a substrate of this kinase [542]. In ad-
dition to this pathway, protein kinase D1 PKD1 (PKC-μ), newly classiﬁed
as belonging to the CaMK group based on characteristics of its kinase
domain (discussed in Ref. [543]), has been shown to participate in
VEGF-mediated angiogenesis. This is accomplished by phosphorylation
of histone deacetylases 5 and 7 and thus releasing the repression of
MEF2-regulated transcription (reviewed in Ref. [543]). The formation of
new capillary tubes in vitro also results in the expression of the CEC5
gene in endothelial cells. This genemay encode a new CaMKwith certain
similarities but distinct from CaMK-II and CASK [544].iphenyl-1-piperidinyl)-propyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-piridine-3,5-
pidermal growth factor; Egr-1, early growth response protein 1; ER, estrogen receptor;
K1, mitogen-activated protein kinase kinase 1; TFP, triﬂuoperazine; TRAIL, TNF-related
the related compound J-18.
d.
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pressingGrb7 or Grb7Vdeletionmutants lacking the CaM-BDpresented
strong anti-angiogenic activity when assayed in vitro, as compared to
media conditioned by cells expressing wild type Grb7 or Grb7V [279].
This suggested the participation of Grb7 in angiogenic processes with
CaM involvement. In this context and of relevance for tumor-
associated angiogenesis, the stable expression of EYFP-Grb7 deletion
mutant in rat glioma C6 cells stereotaxic implantated in the brain pro-
duced tumors with lower angiogenic capacity and of smaller size than
those generated by cells expressing EYFP-Grb7 or EYFP [281].
6.3. Calmodulin and tumor metastasis
Multiple genes control the metastatic invasiveness of tumor cells.
Among these are the MTS1 gene, encoding the Ca2+-binding protein
metastasin 1 (also denoted S100A4), that is highly expressed in tumor
cells with high metastatic potential (review in Ref. [545]); the metasta-
sis suppressor gene denoted NM23 (reviewed in Ref. [546]); and the
GRB7 gene encoding the adaptor protein Grb7 (reviewed in Refs.
[278,547]). Interestingly, in highly metastatic murine melanoma cells
the CaM inhibitor W-7 downregulated the expression of theMTS1 and
NM23 genes [548]. Moreover, this CaM antagonist also inhibited the
development of metastasis of primary Lewis lung carcinoma in a
mouse model [549]. Deletion of the CaM-BD of Grb7 impaired cell at-
tachment to the extracellular matrix and cell migration [281,550],
which may be important in metastasis. This deletion also prevented
the entry of this protein into the nucleus [551]. Overexpression of the
CaM-binding hormone-regulated proliferation-associated protein 20
(HRPAP20) in breast tumor cells appears to be associatedwith their en-
hanced invasiveness by increased secretion of the matrix metallopro-
teinase 9 (MMP-9) [552]. This process may be CaM-dependent as
tumor cells expressing a mutant HRPAP20 protein lacking the capacity
to bind CaM fail to increase MMP-9 secretion and subsequent invasion.
In prostate cancer it has been shown that tumor cell lines derived
from bone metastasis express Notch-1 and the α, β, γ and δ isoforms
of CaMK-II. This is in contrast to prostate tumor cell lines not derived
from bone metastasis, which lack the Notch-1 receptor and some
CaMK-II isoforms, underscoring the implication of these kinases in
Notch signaling and metastasis. CaMK-II does not appear to regulate
the activity of the γ-secretase, responsible for the cleavage of Notch-1
necessary for its translocation to the nucleus [553]. The epithelial–
mesenchymal transition (EMT) is an important phenomenon associated
with metastatic invasion. In this context, Bergamaschi et al. [554] dem-
onstrated ampliﬁcation of the gene encoding CaMK-I (isoform D) in
samples of triple-negative (estrogen, progesterone and ErbB2 negative)
basal breast cancer patients, and found that engineered overexpression
of this kinase in non-tumorigenic breast epithelial cells resulted in the
loss of cell–cell adhesion and increased cell migration as well as inva-
siveness associated to EMT phenotypic changes. In addition, Wang
et al. [555] have recently shown that the interaction of Ca2+/CaM with
the p68 RNA helicase promotes tumor cell migration and metastasis,
as these processes were inhibited by a peptide that spans and blocks
the IQ motif of p68 in two different animal models.
6.4. Calmodulin in tumor stem cells
Cancer stem cells form a small population of self-renewing cells
within tumors that have the ability of unlimited proliferation in contrast
to the majority of more differentiated cancer cells, which form the bulk
mass of the tumor. These stem cells are responsible for tumor growth
and the relapse of patients undergoing currently standard anti-tumor
therapy, as they aremore resistant to chemotherapeutic agents and ion-
izing radiation. Speciﬁcally targeting these cells is expected to open the
path for more effective therapies (reviewed in Refs. [556–559]).
Knowledge of the differentiation mechanisms of normal stem cells is
of upmost importance to understand the physiological role of this cellsubpopulation. Various CaM-dependent systems are known to play
prominent roles in the differentiation of a variety of cell types. These in-
clude neurons (reviewed in Ref. [560]),where for example the expression
of CaM and actin follows a similar spatio-temporal pattern during neurite
outgrowth [561], and the δ isoform of CaMK-II, which participates in
the outgrowth of neurites in embryonal carcinoma cells [562]. CaM
also plays a role in the differentiation of bone cells involving both osteo-
blasts and osteoclasts (reviewed in Refs. [563,564]). As an additional ex-
ample, CaMK-IV plays an essential role in hematopoietic stem cells
differentiation, as demonstrated in Camk4 knockout cells [565]. In neuro-
blastoma cells, used as a model of neural stem/progenitor cells, the
CaMKK/CaMK-IV system is one of the decision-making centers for either
inducingproliferation, by phosphorylation and activation of the transcrip-
tion factors CREB and ATF1, or differentiation, after repressing CaMK-IV
activity for example with retinoic acid [566].
CaM plays important roles in the growth of myeloid and erythroid
progenitor cells, as different CaM antagonists inhibited cytokine-
stimulated colony formation by these cells [567], suggesting that CaM
may play a similar role in leukemia-stem cells. Hematopoietic stem cells
and progenitor cells are subjected to the control of different cytokines in-
cluding the stem cell factor (SCF), which is the ligand of the tyrosine ki-
nase receptor c-Kit (reviewed in Ref. [568]). Interestingly, SCF has been
shown to have a synergistic effect with other cytokines such as IL-3, IL-6
or granulocyte colony-stimulating factor (G-CSF) in the induction of a
68 kDa CaM-binding protein coincidingwith an increase in thymidine ki-
nase activity, implicated in the regulation of the G1/S transition inmyelo-
blastic progenitor cells [569,570]. Finding similarities and speciﬁc
differences in the CaM-mediated mechanisms controlling the functional-
ity of normal stemcells and their tumor counterparts could be of great im-
portance to uncover new potential therapeutic targets.
It has beendemonstrated that somepathways responsible for drug re-
sistance in cancer stem cells are controlled by CaM-dependent systems
such as different CaMKs, which are potential target for therapeutic inter-
vention (reviewed in Ref. [571]). Hypoxia also plays amajor role in tumor
progression as it controls tumor stem cell division, and the major regula-
tor of hypoxia-induced gene transcription HIF is known to be under the
control of CaM [536–539]. In glioblastoma stem cells for example
HIF-2α induces the expression of different genes, someofwhich aremod-
ulated by CaM, as for example NFAT-2, which participates in the CaN
pathway [572]. In leukemic blastic cells, however, the expression of CaN
and other phosphatases are rather low when they are in an early stage
to become pluripotent stem cells [573]. It has been shown that the ex-
pression of the CaM-dependent transcription factor CAMTA1 reduces
the formation of neurospheres and the rate of glioblastoma growth by
a mechanism implicating miRNAs, suggesting that this transcriptional
activator might also play an important role in glioblastoma stem
cells [574]. Highly interesting is the fact that CaMK-IV has been shown
to mediate the epigenetic control of embryonic carcinoma stem
cell differentiation. This kinase phosphorylates histone deacetylases
inhibiting their activity during the experimental differentiation of these
cells into cardiomyocytes [575].
6.5. Calmodulin-directed pharmacological targeting of tumor cells
Multiple CaM inhibitors with distinct chemical structures have been
used to inhibit tumor cell growth of different origins and species either
in culture or in vivo, as for example: ER-positive and ER-negative breast
adenocarcinomas [439,528,576–578], lung carcinomas [579,580], colon
carcinomas [332,333,581], ovary cystadenocarcinoma [582,583], liver
hepatocellular carcinoma [584,585], thyroid papillary adenocarcinoma
[586], melanomas [133,164], sarcomas [587], pituitary tumors [588],
gliomas [87,589–591], and leukemia cells [87,154,592–594] (Table 3).
In addition, the CaM antagonist W-7 has been shown to prevent
chemical-induced carcinogenesis in a classical skin tumor model
[595], and therefore implicating the Ca2+/CaM complex in tumor pro-
motion. There are many natural compounds isolated from plant or
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others, which are potent CaM inhibitors (reviewed in Ref. [596]).
These compounds may be of therapeutic interest but are so far mostly
unexplored.
It is important to point out as mentioned in the previous sections that
CaMantagonistsmay also inhibitmechanisms responsible for the prolifer-
ation of normal cells, as demonstrated in a variety of cell types (see for ex-
ample among others Refs. [151,152,162,164,172,320,321,567,597–602])
(Table 4). Moreover, in some instances CaM inhibitors appear to be less
effective in transformed than in normal cells (reviewed in Ref. [77]), as
tumor cells appear to be defective in a variety of CaM-dependent mecha-
nisms responsible for the correct and ordered function of cell proliferation
(reviewed in Refs. [77,78]). This casts doubts on the efﬁcacy of these
compounds as potential therapeutic agents against cancer.
Notwithstanding the positive role exerted by CaM in the ordered
control of the cell cycle and subsequent cell proliferation events, CaM
also plays a relevant role inducing cell cycle arrest uponDNAdamageme-
diated by genotoxic stress, such as ionizing radiation [603]. Therefore, the
use of anti-CaMagents and radiation therapymight not be awise strategy
to be jointly followed for cancer treatment. In addition, and related with
this, as different actions of CaM are mediated by CaMK-II, the activation
of this kinase via ionizing radiation-induced Ca2+ entry through transient
receptor potential vanilloid 5/6 (TRPV5/6)-like nonselective cation chan-
nels results in cell cycle arrest at G2/M, thus facilitating the survival of leu-
kemia cells due to a greater chance of DNA repair [604]. The mechanisms
of action of CaM antagonists when arresting tumor cell growth could also
be due to somegeneral non-speciﬁc toxic effect, such as inhibiting protein
synthesis as described in Ehrlich ascites tumor cells [605], or by other
specializedmechanisms suchas inducing apoptotic cell death for exampleTable 4
Effects of distinct CaM antagonists on non-tumor cells.
CaM antagonist Cell/tissue/organ Origin
Calmidazolium (R24571) NRK cells (kidney) Rat
PtK2 cells (kidney) Rat-kangaroo
(Potorous tridac
Lymphocytes (from AD patients) Human
Chlorpromazine T lymphocytes Human
Chlorpromazine sulfoxide T lymphocytes Human
D-hexapeptidesa NRK cells (kidney) Rat
Liver cells Rat
Fendiline Keratinocytes (skin) (primary) Human
Inhibitory peptideb COS-7 cells (kidney) Green monkey
(Cercopithecus a
Iodo-C8-W-7 Keratinocytes (epidermis) (primary) Human
J-8 NRK cells (kidney) Rat
Tamoxifen Platelet Human
Triﬂuoperazine Myeloid and erythroid progenitor cells Human
Fetal glioblasts Rat
T lymphocytes Human
Platelet Human
W-13 CHO-K1 cells (ovary) Hamster
NRK cells (kidney) Rat
Myeloid and erythroid progenitor cells Human
W-7 CHO-K1 cells (ovary) Hamster
Fibroblasts (foreskin dermis) (primary) Human
Keratinocytes (epidermis) (primary) Human
Gastric mucosal cells Rabbit
NRK cells (kidney) Rat
PtK2 cells (kidney) Rat-kangaroo
(Potorous tridac
Vascular endothelial cells (umbilical vein) Human
Myeloid and erythroid progenitor cells Human
Platelet Human
Fetal glioblasts Rat
AD, Alzheimer's disease; CHO, Chinese ovary hamster; GMF, glia maturation factor; NLS, nucle
a Synthetic combinatorial library D-hexapeptides isolated as inhibitors of PDE.
b CaM inhibitor peptide based on tandem repeats of the CaM-BD of MLCK creating a NLS toin breast and pituitary tumor cells [588] (see Section 4.6 for additional
examples).
The inhibition of proliferation induced by CaM antagonists in general
is directly correlated with their afﬁnity for CaM [589,591,593]. However,
some of the actions of CaM antagonists might be unspeciﬁc. In ovarian
cancer cells for example W-5 was surprisingly reported to be more
potent than W-7 [582,583], even though W-5 has a lower afﬁnity for
CaM than W-7 [606], since the absence of a chlorine atom in W-5 (and
in W-12) might hinder efﬁcient entry of these compounds into the cell.
Nevertheless, and in agreement with its lower afﬁnity for CaM, W-5
was shown to be mostly ineffective or having weaker effect than W-7
inhibiting the growth ofmurine sarcoma in vivo [587], cells neoplastically
transformed by ASV [163], chemically-induced rat glioblastoma cells
[590], or human leukemia cells [592], among many other examples.
This suggests that the effects of these CaM antagonists could depend to
some extent on the physiological context existing in ovarian cancer
cells as compared to cells from other origins. W-5 was also shown to ac-
tivate DNA synthesis at low concentrations in fetal glioblasts, similar to
W-7 and triﬂuoperazine, suggesting a biphasic and non-speciﬁc effects
of these compounds [597]. Another example of ambiguous effects of po-
tential CaM antagonists is the vinblastine-derivative KAR-2, which, al-
though able to interact with CaM in the absence and presence of Ca2+,
appears to lack anti-CaM activity because it does not prevent CaM
interacting with most tested targets, thus explaining its low toxicity
in vivo [607,608].
CaM antagonists have also been tested in combination with clinically
used anti-tumor drugs because they enhance their anti-proliferative ac-
tions (Table 5). For example, combining the CaM antagonist clomipra-
mine and the alkaloid vincristine, a mitotic inhibitor that preventsEffect References
Inhibits nuclear localization of Cdk4/cyclin D1 [321]
tylis)
Inhibits mitosis (metaphase) [344]
Dephosphorylates pRb [643]
Inhibits PHA-induced mitogenesis [598]
Inhibits PHA-induced mitogenesis [598]
Inhibits DNA synthesis [602]
Inhibits in vivo liver regeneration (after partial hepatectomy) [602]
Inhibits DNA synthesis [599]
ethiops)
Inhibits DNA synthesis [172]
Inhibits cell proliferation (more potently than W-7) [164]
Inhibits nuclear localization of Cdk4/cyclin D1 [321]
Iduces apoptosis and subsequent thrombocytopenia [426]
Inhibits colony formation [567]
Inhibits GMF-induced mitogenesis [597]
Inhibits PHA-induced mitogenesis [598,600]
Iduces apoptosis and subsequent thrombocytopenia [426]
Inhibits cell proliferation Cells arrested at early G0/G1 and
G1/S, inhibiting entry and progression through S. No effect
on G2 progression or from M to next G1
[151,152]
Inhibits DNA synthesis pRb phosphorylation, Cdk2/Cdk4
activation and nuclear localization of Cdk4/cyclin D1
[321]
Inhibits colony formation [567]
Inhibits cell proliferation Cells arrested at G1/S [162]
Inhibits cell proliferation [164]
Inhibits cell proliferation Cells arrested at G1/S [164]
Inhibits cell proliferation [601]
Inhibits nuclear localization of Cdk4/cyclin D1 [321]
tylis)
Inhibits mitosis (metaphase) [344]
Inhibits DNA synthesis and pRb phosphorylation [320]
Inhibits colony formation [567]
Iduces apoptosis and subsequent thrombocytopenia [426]
Inhibits GMF-induced mitogenesis [597]
ar localization sequence; NRK, normal rat kidney; PHA, phytohemagglutinin.
target the nucleus.
Table 5
Synergistic effects of CaM antagonists and chemotherapeutic agents.
CaM antagonist Tumor/cell/tissue Origin Effect References
Acridone derivatives KBChR-8-5 cells (HeLa cell variant) Human Reversal of MDR (vinblastine) [618]
[620]
Chlorpromazine Lymphocytic leukemia P388 cells Mouse Enhances cellular retention and cytotoxicity of Adriamycin [612]
Clomipramine Leukemia (lymphoblastic T and B cells, and
myelogenous cells)
Mouse Circumvents resistance to vincristine in vivo [609,610]
[611]a
E2 Leukemia K562 cells Human Reversal of MDR (doxorubicin) [619]
EBB Breast adenocarcinoma MCF-7/ADR cells Human Reversal of MDR (doxorubicin) [621]
Phenothiazine (thiodiphenylamine) Colon adenocarcinoma WiDr cells Human Potentiates the action of methotrexate and
5-FdUrd (possible reduced DNA repair)
[581]
Phenothiazinesb Glioma C6 cells Rat Potentiates the action of bleomycin [591]
Promethazine Colon adenocarcinoma WiDr cells Human Potentiates the action of methotrexate and 5-FdUrd
(possible reduced DNA repair)
[581]
Triﬂuoperazine EMT6/Ca/VJAC tumor cells Mouse In synergy with heat (44 °C) strongly enhances
bleomycin cytotoxicity
[616]
[611]a
Cancer patients Human Synergistic improved response (4/19 cases) with
bleomycin in a clinical trial
[86,87]a
Breast cancer ER-positive MCF-7 and ER-negative
MDA-MB-468 cells, and primary ER-positive cells
from cancer patients
Human Synergy with tamoxifen inducing apoptosis [438]
Lymphocytic leukemia P388 cells Mouse Reversal of MDR (anthrapyrazoles and anthracyclines) [617]
Enhances cellular retention and cytotoxicity
of Adriamycin
[612]
Promyelocytic leukemia HL-60/ADR0.05 cells
(Adriamycin-resistant)
Human Enhances of cytotoxicity etoposide (VP-16) by
inducing TOPO-II-mediated DNA damage
[455]
W-5 Cystadenocarcinoma ovary cells Human Potentiates the action of doxorubicin
(Adriamycin) and 5-ﬂuorouracil
[582,615]
W-7 Cystadenocarcinoma ovary cells Human Potentiates the action of doxorubicin
(Adriamycin) and 5-ﬂuorouracil
[582,615]
Colon adenocarcinoma WiDr cells Human Potentiates the action of methotrexate
and 5-FdUrd (possible reduced DNA repair)
[581]
Breast cancer ER-positive MCF-7 and ER-negative
MDA-MB-468 cells, and primary ER-positive cells
from cancer patients
Human Synergy with tamoxifen inducing apoptosis [438]
5-FdUrd, 5-ﬂuorodeoxyuridine; ER, estrogen receptor; MDR, multidrug resistant; TOPO-II, topoisomerase II.
a Review article.
b Assay of a family of related neuroleptic antipsychotic drugs.
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drug particularly in leukemia cells resistant to this latter agent [609,610]
(reviewed in Ref. [611]). In human ovarian serous cystadecarcinoma
cells the combination of the CaM antagonists W-5 or W-7 with the
DNA-intercalating drug doxorubicin (Adriamycin™), or the DNA-
crosslinking drug cisplatin, also potentiates the action of these drugs
[582]. Furthermore, chlorpromazine and triﬂuoperazine both enhanced
the retention of Adriamycin™ and its cytotoxicity in mouse lymphocytic
leukemia cells, particularly strong in a resistant clone as compared to
its sensitive counterpart [612]. As an additional example, combining dif-
ferent CaM antagonists with the DNA-damaging agents methotrexate or
5-ﬂuorodeoxyuridine (5-FdUrd) enhanced the cytotoxic effects of these
drugs in human colon adenocarcinoma cells [581]. Furthermore,
downregulating the expression of CaM using siRNA against the transcript
of the CaMgene CALM1 in HeLa cells potentiated the action of the chemo-
therapeutic agent doxorubicin and themitotic inhibitor paclitaxel (Taxol),
but not the inhibitory action of cisplatin [613].
The effect of W-5 andW-7 increasing the uptake of the thymidylate
synthase inhibitor 5-ﬂuorouracil or the uptake of cisplatin in cells resis-
tant to this agent, and hence synergistically arresting cell proliferation,
has been reported in ovarian tumor cells [614,615]. Moreover, a syner-
gistic effect of several phenothiazines, including TFP, in combination
with heat treatment, enhancing the action of the chemotherapeutic
DNA-breaking agent bleomycin has been observed [591,616] (reviewed
in Ref. [611]). The action of many CaM antagonists reverting tumor cells
resistance to different chemotherapeutic agents has been further stud-
ied in numerous tumors [617–621]. This underscores the direct control
that the Ca2+/CaM complex may exert on the P-glycoprotein, a trans-
porter mostly responsible for multidrug-resistant in tumor cells [622].
The pharmacological inhibition of CaM-dependent enzymes in
tumor cells has been attempted as well, most prominently targetingthe different CaMKs isoforms (reviewed in Ref. [623]). In this context
and as an example, the CaMK-II inhibitor KN-93 has been proposed as
a therapeutic agent for treating choriocarcinomas [231]. In addition, it
has been demonstrated that berbamine, a compound isolated from the
traditional Chinese herbal medicine Berberis amurensis, inhibits the pro-
liferation of human chronicmyeloid leukemia cells and liver cancer cells
by blocking the catalytic site of CaMK-II inhibiting its activity [624,625].
Inhibiting the upstreamCaMKKs has also been considered for therapeu-
tic purpose. CaMKK2 has been proposed as a therapeutic target in
androgen-dependent prostate cancer, as this kinase is transcriptionally
regulated by the androgen receptor, contributing to enhanced prolifer-
ation of the tumor cells and subsequent tumor progression [626]. On the
contrary, the targeted inhibition of CaN generally used for immunosup-
pression might have instead some tumor-promoting effects. Particular-
ly, skin squamous-cell carcinomas may be induce because of the
enhancement of the carcinogenic potential of keratinocyte tumor stem
cells, as it happens in patients undergoing immunosuppressive therapy
(reviewed in Refs. [627,628]). Along this line, it has been reported that
substituting CaN inhibitors by alternative immunosuppressive agents,
such as for example mTOR inhibitors, resulted in a drastic and consoli-
dated reduction in the number of new skin tumors [629].
7. Concluding remarks and future perspectives
Because of their potential toxicity, the systemic use of CaMantagonists
in the clinic may be barred or drastically restricted, perhaps for local
tumor-targeted administration only. An alternative to be explored could
be the targeted-inhibition of the binding site(s) for CaM in speciﬁc
CaM-binding proteins, particularly if the activity of these proteins is
subverted in tumor cells. Additionally, searching mutations affecting the
CaM-dependentmechanisms in tumor cells couldbe useful to understand
425M.W. Berchtold, A. Villalobo / Biochimica et Biophysica Acta 1843 (2014) 398–435some pathophysiological processes in cancer, and helpful for diagnostic/
prognostic purpose and/or for predicting survival expectancy. To study
how essential CaM-dependent mechanisms work in normal and tumor
stem cells could also help to understand basic tumorigenic processes.
Studies in this area could be important to develop methods to target
CaM-dependent systems in restricted tumor cell populations and/or in
certain phases of tumor development, thus opening speciﬁc therapeutic
windows, as with DNA-damaging agents, where implementation of this
therapy may be useful in personalized medicine if CaM-dependent
pathways are known to be out of control in a subset of cancer patients.
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